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ABSTRACT

A method for modifying a surface by generating nanotubes at
one or more selected sites on the surface, the surface includ
ing a first metal. The method includes the steps of positioning
at least one cathode and at least one anode relative to the
surface in an electrolyte solution including a fluoride salt of a
second metal, and applying a voltage between the at least one
anode and the at least one cathode sufficient to generate
nanotubes at one or more selected sites on the surface and to
inhibit nanotube formation at one or more of the other
selected sites, wherein the nanotubes include the first metal
and the second metal.
22 Claims, 32 Drawing Sheets
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COMPOSITIONS, METHODS AND DEVICES
FOR GENERATING NANOTUBES ON A
SURFACE

defined by the invention were isolated or otherwise manufac
tured in connection with the examples provided below. Other
features and advantages of the invention will be apparent
from the detailed description, and from the claims.
In one embodiment the invention provides a method for
modifying a surface by generating nanotubes at one or more
selected sites on the surface, the surface including a first
metal. The method includes the steps of positioning at least
one cathode and at least one anode relative to the surface in an
electrolyte solution including a fluoride salt of a second
metal; and applying a voltage between the at least one anode
and the at least one cathode sufficient to generate nano tubes at
one or more selected sites on the surface and to inhibit nano
tube formation at one or more of the other selected sites,
wherein the nanotubes include the first metal and the second
metal.
The invention also provides a titanium or titanium alloy
surface modified according to the disclosed methods, and a
biomedical implant or device having a surface, at least a
portion of which is modified according to the disclosed meth
ods.
The invention further provides a method for modifying a
surface by generating nanotubes at one or more selected sites
on the surface, the surface including titanium. The method
includes the steps of positioning at least one cathode and at
least one anode relative to the surface in an electrolyte solu
tion including silver; and applying a voltage between the at
least one anode and the at least one cathode sufficient to
generate nanotubes at one or more selected sites on the sur
face and to inhibit nanotube formation at one or more of the
other selected sites, wherein the nanotubes include titanium
and silver.
In one aspect, the invention provides a method for modi
fying a metal surface to generate nanotubes at one or more
selected sites on the surface, the method involving position
ing at least one cathode and one or more anodes relative to a
metal surface in an electrolyte solution, where the anodes are
in proximity to the metal surface; and applying a voltage
between the one or more anodes and the cathodes sufficient to
generate nano tubes at one or more selected sites and to inhibit
nanotube formation at other selected sites.
In another aspect, the invention provides a method for
modifying a metal surface at one or more selected sites on the
surface, the method involving positioning one or more anodes
in proximity to a metal surface in an electrolyte solution; and
applying a voltage between the one or more anodes and one or
more cathodes sufficient to modify the metal surface at one or
more selected sites and to inhibit modification at other
selected sites.
In an additional aspect, the invention provides a method for
modifying a metal surface to generate nanotubes at one or
more selected sites on the surface, the method involving posi
tioning at least one cathode and an anode array having a
plurality of anodes in an electrolyte solution, where the
anodes are in proximity to the metal surface; and applying a
voltage between the cathode and the anode array sufficient to
generate nano tubes at one or more selected sites and to inhibit
nanotube formation at other selected sites.
In still another aspect, the invention provides a device for
modifying a titanium or titanium alloy surface to form nano
tubes at one or more selected sites on the surface, having at
least one cathode, one or more anodes and a titanium or
titanium alloy surface in an electrolyte solution, where the
one or more anodes is in proximity to the surface; at least one
power supply in electrical communication with the cathode
(s) and anode(s), where nanotubes are formed on the surface
when voltage is applied in the presence of an electrolyte

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation-in-part of PCT/US2011/
051578, filed Sep. 14, 2011, which claims the benefit of U.S.
Provisional Application 61/382,761, filed Sep. 14, 2010, and
is a continuation-in-part of PCT/US2012/055163, filed Sep.
14,2012, which claims the benefit of U.S. Provisional Appli
cation No. 61/534,739, filed Sep. 14,2011; each of the abovementioned applications is incorporated by reference herein in
its entirety.
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FIELD OF THE INVENTION
The present invention relates to methods and apparatus for
generating nanotubes on a surface.

20

BACKGROUND OF THE INVENTION
Due to their biocompatibility, titanium and titanium alloys
are used in a variety of biomedical devices, including ortho
pedic and dental implants. Titanium and titanium alloys are
ideally suited to such applications because they are not only
corrosion resistant, but also have the ability to be integrated
into bone. Titanium can be subjected to surface modification
to alter its biocompatibility, for example by electrochemical
etching. Electrochemical etching generates nanotubes of tita
nium oxide. Electrochemical etching and other modifications
can be used to modulate the hydrophobicity/hydrophilicity of
the surface. Enhancing hydrophobicity results in a surface
that is not easily wettable and sheds water. Enhancing hydrophilicity results in a surface that is wettable and supports cell
growth. For example, titania nano tubes can be produced by
etching titanium foil in an aqueous electrolyte containing
fluoride ions. Conventional methods use a two-electrode DC
anodization process that is carried out in a vessel containing
an aqueous electrolyte containing fluoride ions, such as
hydrofluoric acid, with the titanium foil acting as the working
anode, and a platinum mesh acting as the cathode. Conven
tional methods have proved unsatisfactory because they typi
cally require the use of expensive metals, such as platinum,
and/or hazardous chemicals, such as hydrofluoric acid, as a
fluoride ion source. Moreover, their commercial applicability
is limited because they are most suitable for the uniform
modification of small flat titanium foils. Improved methods
for modifying surfaces having complex geometries are
urgently required for use in orthopedic and dental applica
tions. Advantageously, such methods would provide for the
selective modification of portions of the surface using nonhazardous electrolytes and inexpensive electrodes.
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SUMMARY OF THE INVENTION
As described below, the present invention features compo
sitions, devices, and methods for generating nanotubes on a
surface (e.g., a titanium or titanium alloy surface) and for
incorporating an antimicrobial agent into the nanotubes in a
controlled manner.
The invention provides for the modification of a surface to
generate nanotubes at selected sites on the surface using one
or more point or cylindrical graphite electrodes. In one
embodiment, the methods of the invention feature the use of
non-hazardous electrolytes. Compositions and articles

60

65
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solution; and a support for positioning the cathode and one or
more anodes relative to the surface. In various embodiments,
the device has two or more point or cylindrical cathodes or
anodes positioned relative to selected sites on the surface.
In various embodiments of any of the aspects delineated
herein, the modification of the metal surface involves nano
tubes or the generation of nanotubes. In various embodiments
of any of the aspects delineated herein, the surface is polished
and/or sequentially sonicated prior to anodization. In various
embodiments of any of the aspects delineated herein, the
surface is titanium or a titanium alloy. In various embodi
ments, the nano tubes are T102 nano tubes. In particular
embodiments, the T102 nanotubes have no detectable traces
of other elements. In various embodiments of any of the
aspects delineated herein, the nanotubes formed at one
selected site are the same or different in length and diameter
from nanotubes formed at another site on the surface. In
various embodiments of any of the aspects delineated herein,
the surface is present on a biomedical implant or medical
device. In particular embodiments, the implant is a dental
implant, cardiovascular implant, neurological implant, neu
rovascular implant, gastrointestinal implant, muscular
implant, orthopedic implant, cochlear implant, and/or ocular
implant. In specific embodiments, the orthopedic implant is a
joint implant, spinal implant, screw, pin, rod, and/or plate. In
various embodiments of any of the aspects delineated herein,
the method involves loading the nanotubes with an effective
amount of a biologically active agent. In various embodi
ments of any of the aspects delineated herein, the nanotubes
contain or have an effective amount of an agent. In various
embodiments, the agent is an antimicrobial, anti-inflamma
tory, growth factor, or statin.
In various embodiments of any of the aspects delineated
herein, the electrolyte solution contains NH4F. In various
embodiments the electrolyte solution contains ethylene gly
col or propylene glycol. In various embodiments of any of the
aspects delineated herein, the anodes and cathode are graph
ite. In various embodiments of any of the aspects delineated
herein, the cathode or anodes are point or cylindrical elec
trodes. In various embodiments of any of the aspects delin
eated herein, the applied voltage is +60 VDC. In various
embodiments of any of the aspects delineated herein, the
anode is positioned between 0.01-10 mm from the surface. In
various embodiments of any of the aspects delineated herein,
the cathode is positioned between 1-100 mm from the sur
face. In various embodiments of any of the aspects delineated
herein, the voltage, time for which the voltage is applied, and
distance between the anodes and the surface is varied.
In various embodiments of any of the aspects delineated
herein, surface modification is inhibited on a portion of the
metal surface in proximity to at least one of the anodes or
array of anodes. In various embodiments of any of the aspects
delineated herein, nanotube growth is reduced or absent at
one or more selected sites on the surface. In various embodi
ments of any o f the aspects delineated herein, the distance of
the cathode and/or anode relative to the surface, voltage, and
time for which the voltage is applied are selected to form
nano tubes whose length and/or diameter differs between sites
on the surface.
In various embodiments of any of the aspects delineated
herein, the surface is thermally treated following modifica
tion. In particular embodiments, the thermal treatment is car
ried out between 300 and 500 [deg.JC. In various embodi
ments of any of the aspects delineated herein, the method
increases the wettability of the surface. In various embodi
ments of any of the aspects delineated herein, the method
enhances the ability of the surface to support cell growth. In

various embodiments o f any of the aspects delineated herein,
the nanotubes contain a cell. In particular embodiments, the
cell is an osteoblast, fibroblast, or a progenitor or a descendant
of the cell.
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By “agent” is meant any small compound, antibody,
nucleic acid molecule, or polypeptide, or fragments thereof.
By “antimicrobial” is meant an agent that inhibits or sta
bilizes the proliferation or survival of a microbe. In one
embodiment, a bacteriostatic agent is an antimicrobial. In
other embodiments, any agent that kills a microbe (e.g., bac
terium, fungus, virus) is an antimicrobial.
By “anti-inflammatory” is meant an agent that reduces the
severity or symptoms of an inflammatory reaction in a tissue.
An inflammatory reaction within tissue is generally charac
terized by leukocyte infiltration, edema, redness, pain, and/or
neovascularization. Inflammation can also be measured by
analyzing levels of cytokines or any other inflammatory
marker.
By “biomedical implant” is meant any exogenous material
that is introduced in to the body of a subject.
By “descendant” is meant a cell type that arises from the
cell division and/or differentiation of a progenitor cell.
By “effective amount” is meant the amount of an agent
required to ameliorate the symptoms of a disease relative to
an untreated patient. The effective amount of active agent(s)
used to practice the present invention for therapeutic treat
ment of a disease varies depending upon the manner of
administration, the age, body weight, and general health of
the subject. Ultimately, the attending physician or veterinar
ian will decide the appropriate amount and dosage regimen.
Such amount is referred to as an “effective” amount.
By “elution rate” is meant the time required for an agent to
be substantially released from a composition. Elution can be
measured by determining how much of an agent remains
within the composition or by measuring how much of an
agent has been released into the composition’s surroundings.
Elution may be partial (10%, 25%, 50%, 75%, 80%, 85%,
90%, 95% or more) or complete. In one preferred embodi
ment, the agent continues to be released at an effective level
for at least about 3, 4, 5, 6, 7, 8, 9, or 10 days.
By “infection” is meant the presence of one or more patho
gens in a tissue or organ of a host. An infection includes the
proliferation of a microbe (e.g., bacteria, viruses, fungi)
within a tissue of a subject at a site of trauma.
By “progenitor” is meant a cell that gives rise during divi
sion and/or differentiation to another cell type.
By “proximity” is meant a distance sufficient for an anode
to inhibit nanotube formation at a desired site. In one embodi
ment, an anode is in proximity to a site when it is about 1-20
mm from the site.
By “reference” is meant a standard or control condition.
By “selected site” is meant a portion of the surface that is
chosen for modification. In contrast, other portions of the
surface— sites that are not selected— are not modified.
By “subject” is meant a mammal, including, but not limited
to, a human or non-human mammal, such as a bovine, equine,
canine, ovine, or feline.
Ranges provided herein are understood to be shorthand for
all of the values within the range. For example, a range of 1 to
50 is understood to include any number, combination of num
bers, or sub-range from the group consisting 1, 2, 3,4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
2 5 ,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,
42, 43, 44, 45, 46, 47, 48, 49, or 50.
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Unless specifically stated or obvious from context, as used
herein, the term “or” is understood to be inclusive. Unless
specifically stated or obvious from context, as used herein, the
terms “a”, “an”, and “the” are understood to be singular or
plural.
Unless specifically stated or obvious from context, as used
herein, the term “about” is understood as within a range of
normal tolerance in the art, for example within 2 standard
deviations of the mean. About can be understood as within
10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%,
0.05%, or 0.01% of the stated value. Unless otherwise clear
from context, all numerical values provided herein are modi
fied by the term about.
Any compositions or methods provided herein can be com
bined with one or more of any of the other compositions and
methods provided herein.

on annealed and as-anodized TNT surfaces. The increasing
contact angles varied in each case but all o f the TNT samples
increased the surface wettability. FIG. 9B shows the cases of
bare titanium. In these cases, the wettability had little, if any,
change with time.
FIG. 10 is a top view schematic of a basic single graphite
cylinder electrode system to inhibit nano tube growth near the
+60 VDC electrode (marked +), where the titanium substrate
is placed between the electrodes.
FIG. 11 depicts images of the two sides of a titanium
specimen etched using a single graphite cylinder electrode to
inhibit nanotube growth near the +60 VDC electrode as
shown in FIG. 10.
FIG. 12 is a top view schematic of a single graphite cylin
der electrode system to inhibit nanotube growth near the +60
VDC electrode (marked +), where the +60 VDC electrode is
placed between the titanium and the graphite rod electrode.
FIG. 13 depicts images of the two sides of a titanium
specimen etched using a single graphite cylinder electrode to
inhibit nanotube growth near the +60 VDC electrode as
shown in FIG. 12.
FIG. 14 is a top view schematic of a system to inhibit
nanotube growth in one-half of a titanium specimen in which
nanotube growth is inhibited using a graphite cylindrical rod
electrode (marked +), where the electrodes are placed in close
proximity to each other and the titanium substrate.
FIG. 15 depicts images of the two sides of titanium speci
men etched using a single graphite cylinder electrode to
inhibit nanotube growth near +60 VDC electrode in FIG. 14.
FIG. 16 is a schematic of an automated and reconfigurable
nanotube etching system. Each point or rod electrode (1, 2,3,
4 , . . . , n) is supplied with an etching voltage (Vn), an etching
time (Tn), and a standoff distance (Dn) for specific nanotube
dimensions and mechanical stiffness.
FIG. 17 is a graph showing density of adhered MC3T3 cells
as a function of incubation time on the surface of commer
cially pure (cp) Ti (left) and alloy Ti (right) with different
structures. The data confirms the effect of anodization and
annealing in enhancing cell density in comparison to control
bare surfaces for both cp and alloyed substrates. In the cell
density of annealed substrates there was a slight increase in
the case of cp nanotubes compared to alloyed nanotubes
which was due to slightly higher biocompatibility of cp Ti.
FIG. 18 is a graph depicting the effect of nanotube length,
crystallinity, and composition on cell number and attachment.
FIGS. 19A and 19B are images of FIB milled fibroblast
cells obtained from a primary ion beam. Internal structures,
membranes and morphological stability and integrity can be
assessed; moreover, the interface between the cell and the
substrate can be observed. Scale bars are 5 pm (FIG. 19A),
and 10 pm (FIG. 19B).
FIGS. 20A-20D show SEM images of a cross-sectional
view of the cell-nanotube interface (FIGS. 20A and 20B),
milled by the FIB technique and a magnified view of cellnanotube interaction and filopodia growth inside a nanotube
(FIGS. 20C and 20D). Scale bars are 2 pm (FIG. 20A), 1 pm
(FIG. 20B), and 500 nm (FIGS. 20C and 20D).
FIGS. 21A-21G are images showing osteoblast cell inter
action with T i0 2 nanotubes. The extension of osteoblast cells
for adhesion on the nanotubes as well as cell clusters on the
nanotube surface (FIGS. 21A-21C) indicate the ability of the
nanotube structure to promote cell adhesion and growth.
Scale bars are 100 pm (FIG. 21A), 50 pm (FIG. 21B), and 10
pm (FIG. 21C). FIGS. 21D-21F are images showing cell
filopodia attachment and spreading on and between nano
tubes. The nano tubes can act as anchors for cell filopodia to
grab (FIG. 21F) and increase the spreading (FIG. 21D) and
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic of a nanotube etching system. The
cathode electrode shown here is graphite, which was used as
a replacement for platinum (which is more cost-prohibitive).
The same set up was used during etching experiments using
platinum (Pt), copper (Cu), stainless steel, and graphite as
counter electrodes.
FIG. 2 shows SEM images of nanotubes etched with dif
ferent counter electrodes and their corresponding EDS analy
sis: Pt electrode (FIG. 2A), Stainless steel electrode (FIG.
2B), Cu electrode (FIG. 2C), and Graphite electrode (FIG.
2D).
FIG. 3 is a schematic diagram showing a basic electro
chemical nanotube fabrication apparatus.
FIGS. 4A and 4B are images showing nano tubes etched
with graphite electrodes produced according to methods of
the invention. Nanotubes etched with graphite cylindrical
electrode (FIG. 4A) were longer than nanotubes etched with
graphite point electrode (FIG. 4B). Nano tubes etched with a
graphite point electrode have a length useful for orthopedic
applications.
FIGS. 5A and 5B show that varying diameters of T i0 2
nanotubes can be produced using methods of the invention.
FIG. 5A shows SEM images of T i02 nanotubes of varying
diameters. FIG. 5B shows a graph of T i02 nanotube diameter
v. time at 20V, 40V, and 60V.
FIGS. 6A and 6B depict transmission electron microscopy
(TEM) images of T i02 nanotube surfaces (TNT) structured
surfaces. As-synthesized nanotubes are amorphous (FIG.
6A), and annealed nanotubes are crystalline (FIG. 6B).
FIGS. 7A and 7B depict the wettability of T i02 nano tube
surfaces. Representative image comparison of the initial con
tact angles. FIG. 7A shows six samples in total that were
investigated, including pure titanium and titanium alloys hav
ing bare surfaces, not-annealed TNT surfaces, and annealed
TNT surfaces. FIG. 7B shows a plot of results of the contact
angles on the surfaces. The TNT surfaces were more hydro
philic and the annealing effect made the TNT surface superhydrophilic. Contact angle differences were attributed to the
surface properties, in particular the surface roughness, which
could affect the initial contact angle of a water droplet on each
titanium surface.
FIG. 8 shows a comparison of the time-dependent change
of surface wettability of T i02 nanotube surfaces. Annealed
TNT (Pt/alloy), As-grown TNT (Pt/alloy), and bare foil (al
loy) were compared. As time passed, the TNT surface hydrophobicity increased.
FIGS. 9A and 9B depict the comparison of the time-dependent contact angles. FIG. 9A shows water droplet wettability
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improve its attachment (FIG. 21E). Scale bars are 3 pm (FIG.
21D), 500 mn (FIG. 21E), and 1 pm (FIG. 21F). FIG. 21G is
an image showing an osteoblast filopodia—its foot used for
locomotion—anchored to titanium nanotubes and ECM pro
duction on and in between nanotubes during cell migration
and bone matrix deposition. Scale is 50 pm.
FIG. 22A-22F are images of FIB cross sectional milling
revealing titania nanotubes which have been clogged by
osteoblast and calcium deposition on nanotubes as a result of
cell attachment and direct contact with surface. Scale bars are
200 pm (FIG. 22A), 50 pm (FIG. 22B), 20 pm (FIG. 22C), 5
pm (FIGS. 22D and 22F), and 10 pm (FIG. 22E).
FIG. 23 depicts EDS analysis of clogged nanotubes as
shown in a high-resolution scanning electron micrograph (in
set). The clogged nanotubes were visible and composed of Ca
and P (by EDS), the primary components of bone matrix.
Scale bar is 1 pm.
FIGS. 24A and 24B are scanning electron micrograph
images of nanotube-covered Ti6A14V ELI cancellous bone
screws. Scale bars are 1 mm (FIG. 24A) and 1 pm (FIG. 24B).
FIG. 25 is a graph showing the comparison of insertion
torque and pilot-hole diameter for a bare Ti6A14V ELI can
cellous bone screw.
FIG. 26 is a graph showing a comparison of insertion
torque for a bare Ti6A14V ELI cancellous bone screw and a
nanotube-covered Ti6A14V ELI cancellous bone screw.
FIG. 27 is an SEM image of a nanotube-covered bone
screw after insertion and removal in a 5 mm pilot hole in bone
stimulant and subsequent insertion and removal in a 3.2 mm
pilot hole in bone stimulant.
FIG. 28 is an SEM image of a nanotube-covered bone
screw after insertion and removal in a 5 mm pilot hole in bone
stimulant and subsequent insertion and removal in 3.2 mm
pilot hole in bone stimulant, and after cleaning by vaporiza
tion of bone stimulant and sonication cleaning.
FIG. 29 is a graph depicting typical etching current (mA)
vs. time (minutes) for nanotube formation in Ti6A14V at: 60
VDC (top-most curve); 40 VDC (middle curve); and 20 VDC
(bottom-most curve). Mathematical curve fitting shows good
correlation with a natural logarithmic behavior. Because
nanotube morphology is also correlated with etching time,
etching current can be used as a feedback parameter in an
automated production system.
FIGS. 30A and 30B are scanning electron micrograph
images of nanotubes on titanium alloy Ti6A14V fabricated
with AgF-containing electrolyte. Etching conditions were 60
VDC and time of 30 minutes. Nanotube length was approxi
mately 2 microns. Only trace levels of silverwere found when
conducting elemental analysis. Scale bars are 1 pm (FIG. 1A),
and 500 nm (FIG. IB).
FIG. 31 is a scanning electron micrograph image of nano 
tubes on titanium alloy Ti6A14V fabricated with AgF-containing electrolyte. Etching conditions were 60 VDC and time
of 30 minutes. Electrode polarity was immediately reversed
and silver deposition time was 15 minutes.
FIG. 32 shows the relative presence of silver associated
with a nanotube surface, on both an atomic percent presence
and a weight percent presence as measured by eneigy-dispersive X-ray spectroscopy.

conjunction with nanotube formation. In one embodiment,
the secondmetal (e.g., calcium) enhances the surface’s ability
to support mammalian cell growth. In another embodiment,
the second metal (e.g., silver) has anti-microbial activity that
reduces the propensity of the surface to support microbial
(e.g., bacterial, fungal) growth. In yet another embodiment, a
combination of two or more fluoride salts in the electrolyte
(such as, but not limited to, silver fluoride and calcium fluo
ride) will result in the combined properties. In various
embodiments, the invention includes methods for adjusting
the amount of the second metal that is added to the nanotubes
in order to control the properties that the second metal pro
duces.
The invention is based, at least in part, on the following
discoveries: first, that nanotubular structures can be fabri
cated using a benign electrolyte comprising ethylene glycol,
water, and ammonium fluoride, silver fluoride and/or calcium
fluoride; nanotubular structures are fabricated using inexpen
sive graphite rod or graphite point electrodes, rather than
expensive platinum electrodes; third, graphite point elec
trodes can be used to selectively fabricate nanotubes at
desired sites, while concurrently inhibiting generation of
nano tubes at other sites; and finally, that by varying the volt
age applied at each of the electrodes and varying the length of
time the voltage is applied the surface can be selectively
modified at discrete sites with nanotubular structures of
selected lengths. Advantageously, these nanotubes can be
further modified to comprise a second metal. In particular
embodiments, the invention features arrays of electrodes suit
able for selectively modifying surfaces having complex
geometries, such that the growth of nanotubes is permitted at
particular sites and concurrently inhibited at other sites. As
reported in more detail below, nanotubular structures are fab
ricated into Ti6A14V ELI surgical orthopedic cancellous and
cortical bone screws using electrodes of the invention. These
nano tubes survive multiple insertion and removal cycles in an
accepted bone simulant material. Accordingly, the invention
provides benign electrolytes, electrodes (e.g., graphite point
and cylindrical electrodes), and automated devices compris
ing point and/or cylindrical electrodes for fabricating nano
tubes on the surface of pure and Ti6A14V titanium sheets and
Ti6A14V ELI orthopedic hardware by anodization. In certain
embodiments, this process advantageously modifies the sur
face to enhance mammalian cell growth and adhesion and/or
to reduce the surface’s ability to support microbial cell
growth.
Electrolyte
The present invention utilizes electrolytes suitable for use
in the electrochemical etching or modification of surfaces
(e.g., titanium and titanium alloys) to generate nanotubular
structures. The electrolytes used in the invention are advan
tageously free of hydrofluoric acid and other caustic, hazard
ous, or otherwise dangerous sources of fluoride ions. Because
these electrolytes are benign they are suitable for modifica
tion of surfaces to be implanted in a subject to enhance cell
growth and cell adhesion. In particular, the invention utilizes
aqueous electrolytes comprising ethylene glycol or propylene
glycol, water, and a fluoride-containing salt. The fluoridecontaining salt is in solution (i.e., in water). The amount of
water in the electrolyte is about 0.1%, 0.25%, 0.5%, 1-2%,
5%, or 10% (v/v). The fluoride-containing salt may include
one or a combination of fluoride-containing salts (e.g.,
ammonium fluoride, silver fluoride and/or calcium fluoride).
In a particular embodiment, the fluoride-containing salt is
ammonium fluoride. The amount of fluorine atom present in
the electrolyte can be determined or calculated using methods
known in the art. For example, fluorine is about 51% of

5

10

15

20

25

30

35

40

45

50

55

60

DETAILED DESCRIPTION OF THE INVENTION
The present invention generally features compositions and
methods for generating nanotubes on a surface (e.g., a tita
nium or titanium alloy surface) at selected sites and coating
the nanotubes with a second metal or incorporating the sec
ond metal into the nanotubes, either as a separate step or in
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ammonium fluoride by weight. The electrolyte contains about
5-1000 mg fluorine/100 ml (e.g, 5,10, 25, 50, 100, 200, 250,
300, 400, 500, 750, 1000 mg fluorine/ml). In a particular
embodiment, the electrolyte comprises up to 330 mg fluoride
ion/50 ml electrolyte. It has been observed that increasing the
amount of fluoride ion in the electrolyte decreases etch times,
and weaker electrolyte etches more slowly. Etch times range
from 5 minutes-60 minutes (e.g., 5, 10, 15,20,25,30,35,40,
45, 50, 55, 60 minutes). In a specific embodiment, 337 mg
fluorine/100 ml provides a desirable etch time.
Electrodes and Electrode Geometry
Conventional anodization methods use a two-electrode DC
anodization process that is carried out in a vessel containing
an aqueous electrolyte containing fluoride ions, such as
hydrofluoric acid. In this conventional system, titanium foil
acts as the anode and a platinum mesh acts as the cathode. The
use of a platinum cathode increases the cost associated with
anodization. The invention advantageously provides electro
chemical etching methods featuring graphite point and cylin
drical electrodes (e.g., cathodes, anodes), which provide a
significant cost savings.
The invention further provides for the use of one or more
inhibitory electrodes (e.g., anodes) to which voltage (e.g.,
+60 VDC) is applied. The inhibitory electrode selectively
inhibits nanotube fabrication at selected sites on the surface.
This is particularly useful for biomedical implants where cell
growth can be enhanced at desired portions of the implant
surface and inhibited at other sites on the implant surface. In
one embodiment, the formation/inhibition of nanotubes and
the deposition of a second metal is carried out in a single
electrolyte. In another embodiment, the formation/inhibition
of nanotubes is carried out in a first electrolyte (e.g., ammo
nium fluoride) and the deposition of a second metal is carried
out in a second electrolyte (e.g., silver fluoride, calcium fluo
ride).
The invention further features the use of electrode arrays
(e.g., two, three, four, five, six, seven, eight, nine, ten, ormore
electrodes) that are positioned in three-dimensional space
relative to the titanium surface to be modified. This provides
for the growth of nanotubes on surfaces having complex
geometries. In particular embodiments, one or more of the
electrodes is positioned in the electrolyte together with the
surface to be modified. Between +25 and 100 VDC is applied
to one or more of the electrodes. Other electrodes serve as
ground electrodes. In one embodiment, 50, 55, 60, 65, or 70,
110, 120, 150, 175,200V D C or up to the electrolyte break
down voltage is applied to one or more electrodes. The area of
inhibition of nano tube formation may be controlled by adjust
ing the number and/or proximity o f inhibitory anodes. Large
areas of the surface may be inhibited for nanotube formation
by using multiple inhibitory electrodes without limitation
(e.g., over a square foot). Depending on the size of the elec
trode, nanotube formation may be inhibited over smaller
areas (e.g., using a point electrode). It has been observed that
the area of inhibition of nanotube formation is approximately
the diameter of point electrode plus 2x the gap distance (e.g.,
a 1 mm point electrode, 1 mm from surface, yields a zone of
inhibition about 3 mm). Areas where inhibition is inhibited
can be from less than 1 mm2to ameter2 ormore (e.g., 0.1,0.5,
1 ,2,3,4,5,10,25, 50,100,125,150,175,200,300,400, 500,
600, 700, 800, 900, 1000 mm). Additionally, the closer the
anode is to the substrate, the smaller the area of inhibited tube
growth. The ability to modify the formation of nanotubes is
advantageous for modulating cellular interactions with the
surface, e.g., to promote preferential cell growth, encourage
osteoblast growth and/or migration, to prevent fibroblast
growth and/ormigration, orto prevent angiogenesis in a stent.

If desired, an inhibitory electrode may be fabricated of carbon
nanotubes and used to inhibit nanotube formation on a sur
face. Such inhibitory electrodes may be 0.5, 1 mm, 2 mm, or
3 mm in diameter. In general, a point electrode or cylindrical
electrode(s) is positioned at a distance that is between about
0.1, 0.05, 1 mm to about 100 mm or more (e.g., 1, 3, 5, 6, 7,
8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,
85, 90, 95, 100 mm) from the substrate. There should be no
limit to this separation distance. The smallest distance for
position depends on the electrical strength of the electrolyte,
the voltage between the anode and metal substrate, and the
thickness of electrolyte. The gap should be small enough so as
not to exceed the breakdown voltage between electrode and
titanium (i.e., does not arc). Nanotubes are quickly fabricated
with a voltage up to +60 VDC, although other voltages can be
used to fabricate nano tubes having the desired properties.
Such voltage are selected to optimize nanotube length to
support cell growth and to optimize for mechanical stability.
The electrodes in an array may have the same voltages applied
or may have different voltages. They may be at the same
distance from the surface or at different distances.
In particular embodiments, nanotubes are preferentially
formed or inhibited by the positioning of one or more point or
cylindrical electrodes. For example, as shown in FIG. 11,
nanotube growth is inhibited in a substrate in proximity to the
+60 VDC electrode (“the inhibitory electrode or anode”). The
distance between the inhibitory electrode and the substrate is
between about 3-10 mm (e.g., about 3, 4, 5, 6,7, 8, 9, 10 mm)
A smaller separation distance provides a more localized inhi
bition of nanotube etching. The separation distance can be as
small as desired, providing there is sufficient electrolyte
between the electrode(s) and the specimen surface. Nanotube
growth occurs on other portions of the surface that are not in
proximity to the inhibitory electrode. The distance between
the cylindrical graphite ground electrode and the substrate is
between about 50-100 mm (e.g., 50, 60, 70, 80, 90,100). The
substrate whose surface is to be modified can be between the
inhibitory electrode and the ground electrode (as shown in
FIG. 10), or the inhibitory electrode and the ground electrode
can be on the same side of the surface to be modified (as
shown in FIGS. 12 and 14).
Point and cylindrical electrodes can be made of virtually
any conducting material (e.g., platinum, stainless steel, cop
per and graphite). Preferably, the electrode is any electrically
conducting material that does not adversely contaminate the
surface. Small nanotubes may also be generated using nanos
cale electrodes including carbon nanotubes and titanium
nano tubes. In one embodiment, an electrode array comprises
a combination of graphite point electrodes to which current is
applied and a single ground electrode. In another embodi
ment, an electrode array comprises one or a combination of
graphite point electrodes to which current is applied and
ground electrodes, which are also graphite point electrodes.
In some embodiments, electrochemical etching may be moni
tored by color formation, (e.g., when a copper anode is used).
Additionally, electrochemical etching may be monitored
optically (e.g., opaqueness of the electrolyte, UV absorption),
by measuring the formation of titanium in solution, or by
detecting changes in conductivity.
By selecting the voltage of each electrode and/or the tita
nium, nano tube fabrication can be allowed in selected regions
of the titanium and inhibited in other selected regions of the
titanium. If the time that the voltage is applied is also varied
at each of the multiple electrodes in an array nanotubular
structures of varying lengths can be fabricated at desired sites
on the substrate.
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Cylindrical electrodes are typically uncoated strands of
conductive material. Rod electrodes may be composed of
copper, graphite, or other suitable electrically conductive
material. Point electrodes are formed when a strand of copper,
graphite, or other suitable electrically conductive material is
coated with an insulating layer to produce a single electrical
near-point source. Insulating layers include, but are not lim
ited to, plastic heat-shrink tubing, paints, lacquers, epoxies or
other electrically insulating materials compatible with the
electrolyte and the process. By using point and cylindrical
electrodes at the proper locations, distances, voltages, and
times, tubular nanostructures can also be etched on the sur
face of interior features, such as holes and sharp depressions
of regular and irregular shape, interior sharp corners and
concave features, exterior features such as protrusions of
regular and irregular shape, exterior sharp comers and convex
features. Such complex geometries are typically found on the
surface of orthopedic implants or other implantable devices
where such tubular nanostructures are desired.
Nanotube Parameters
In general, the length of a nanotube is a function of the
conditions under which the nano tube was formed. Nano tubu
lar structures are fabricated on the specimen when the voltage
potential of the specimen is higher than surrounding elec
trodes. This is defined as “current leaving” the specimen—
that is charge is moving from a more positive voltage to a
lower voltage at any location on the titanium specimen. If
however, “current enters” the titanium specimen at any loca
tion, nanotube fabrication is inhibited. Under these specified
fabrication conditions, the specimen may or may not be elec
trically connected to the electrochemical etching circuitry.
The specimen may be allowed to electrically “float” without
imposing a particular voltage.
The point electrodes and cylindrical electrodes of the
invention, alone or in arrays, provide for the fabrication of
arrays of nanotubes. By altering the position of the multiple
electrodes relative to the surface, the distances of each of the
electrodes from the surface, the voltage applied to each of the
multiple electrodes, and the length of time of etching, the
properties of the nanotubes can be predictably altered (i.e.,
the length, diameter, pore size).
For example, nanotubes are fabricated to have a wall thick
ness ranging from about 3 nm to about 300 nm (e.g., 3, 5, 10,
15,20,25,50,75,100,125,150,175,200,225,250,300 nm),
preferably 5-10 nm. Nanotubes are fabricated to have an inner
diameter ranging from about 3 nm to about 300 nm (e.g., 3, 5,
10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 300
nm), preferably 30-80 nm. Nanotubes are fabricated to have
an outer diameter ranging from about 3 nm to about 300 nm
(e.g., 3, 5,10,15,20,25, 50,75,100,125,150,175,200,225,
250, 300 nm), preferably 80-120 nm. In some embodiments,
the nanotubes are fabricated at a density of at least about
100,000,000, 200,000,000, or 300,000,000 nanotubes per
square centimeter. Exemplary morphologies of titanium
nanotubes and titanium nanotube surfaces include honey
comb (see, e.g., FIG. 2A) and free-standing nanotubes (see
e.g., FIG. 5A). In other embodiments, the nanotubes are fab
ricated at a density of at least about 25,000,000, 50,000,000,
or 75,000,000 nanotubes per square centimeter (e.g., free
standing nanotubes). The nano tube density may range from
many millions per square centimeter to several billion per
square centimeter for the closely packed honeycomb configu
ration. Nanotubes are fabricated to have a length ranging from
about 1 pm to about 100 pm (e.g., 1, 3, 5, 10, 20, 25, 50, 75,
100). Nanotubes longer than 10 pm are structurally weak and
separate from the metal substrate. Nano tubes are fabricated to
have pores that range in diameter from about 3 nm to about

250 nm (e.g, 3, 5, 10, 15, 20, 25, 50, 75, 100, 125, 150, 175,
200, 225, 250 nm), preferably 10 nm to 100 nm. Advanta
geously, the electrode arrays of the invention allow the sur
face to be heterologously modified. For example, longer
nanotubes can be fabricated at selected sites on the surface,
while shorter nano tubes are formed at other selected sites, and
nanotube formation is inhibited at still other sites.
In other embodiments, the polarity of the anode and cath
ode are reversed such that nanotubes are fabricated over sites
on the surface where nanotube growth was previously inhib
ited. This provides one or more regions of relatively long
nanotubes and one or more regions of shorter nanotubes,
based on the total time and current flow direction of each
region.
In still other embodiments, the polarity of the anode and
cathode are reversed such that a second metal (e.g, silver,
calcium) is deposited on the surface. The length of time that
the voltage is applied determines the amount of metal depos
ited. In one embodiment, the voltage is applied for between
about 5-60 (e.g, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60)
minutes.
Pre-Electrochemical Etching Treatments
Prior to carrying electrochemical etching, the substrate can
be prepared in any of a variety of ways. The surface may be
modified to be smooth or made abrasive. For example, the
surface may be wiped with solvent (e.g, acetone), polished
(e.g, using colloidal S i0 2), sonicated (e.g, sequentially soni
cated in acetone, isopropyl alcohol, and methanol). If desired,
after the pre-treatment the surface is rinsed with deionized
water, and dried (e.g, dried under N2). Pre-treatment may at
least depend in part on the characteristics of the base metal
(e.g, having fine grains or large grains). Alloys are work
hardened and have high density dislocation networks, thus,
abrading the surface exposes grains. To remove exposed
grains, metal alloys may be heat treated, rinsed with acetone,
washed to remove the acetone, machined, and polished.
Post-Electrochemical Etching Treatments
Following electrochemical etching and deposition of a sec
ond metal, the substrate comprising titanium oxide (Ti02)
nanotubes can be treated to further modify the surface prop
erties. T i0 2 occurs in different crystalline structures. In one
embodiment, the surface is heated between about 400 and
500° C. (e.g, 400, 425, 450, 500° C.). Temperatures greater
than 500° C. may also be used. The surface may be heated for
one, two, three, four, or five hours. In one embodiment, the
surface is heated using a rapid thermal annealer. A heating/
cooling rate o f308° C./min was used, and the substrates were
annealed in air at 450° C. for 3 hours. This annealing treat
ment results in phase transformation of T i02 nano tubes from
amorphous to crystalline anatase. Anatase is one of the three
mineral forms of titanium dioxide, the other two being brookite and rutile. Brookite is orthorhombic, and rutile is the
most common polymorph. This post-treatment modifies the
wettability of the surface, alters the surface charge, and may
alter the structural strength, stiffness, and toughness. For
example, heat treatment in N2 and/or C 0 2 may be used to
harden Ti nanotubes or impart other properties.
The invention provides compositions and methods for fab
ricating nanotubes on the surface of a substrate, such as pure
and Ti6A14V titanium sheets and Ti6A14V ELI orthopedic
hardware by electrochemical etching. In certain embodi
ments, the nano tubes enhance cell growth and adhesion to the
surface. In one embodiment, such surface modifications
affect surface wettability and surface potential. Increased
wettability of a surface means that water will spread out more
on such a surface. Wettability also is directly related to the
surface hydrophilicity (i.e, increased hydrophilicity means
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greater wettability) and increased surface energy. Methods
for measuring wettability are known in the art and described
in the Examples. In one embodiment, wettability is assayed
by obtaining contact angles, contact radii, and center-heights
of water droplets on a nanotube surface. Preferably, the con
tact angle is reduced following electrochemical etching and/
or other post-electrochemical etching treatment relative to the
contact angle of untreated titanium. In one embodiment, con
tact angles are decreased by 50-75% compared to the contact
angles of each bare foil.
Medical Implants and Devices
Surfaces such as titanium or titanium alloy surfaces can be
modified using the methods described herein to include T i0 2
nanotubes comprising a second metal that is deposited onto
the surface. In certain embodiments, nanotubes are formed on
titanium and/or titanium alloy implants or devices. In one
embodiment, the invention provides for the modification of
the surface of a titanium port (or portacath) for the delivery of
therapeutics to a subject. Exemplary implants include dental
implants, cardiovascular implants such as a pacemaker, neu
rological implants, neurovascular implants, gastrointestinal
implants, muscular implants, cochlear implants, orthopedic
implants, and ocular implants where bony fixation or cellular
attachment is desirably enhanced. Other implants and devices
include orthopedic devices (e.g., for joint implants, fracture
repairs, spinal implants, screws, rods, plates); surgical
devices (e.g., sutures, staples, anastomosis devices, vertebral
disks, bone pins, suture anchors, hemostatic barriers, clamps,
screws, plates, clips, vascular implants, tissue adhesives and
sealants, tissue scaffolds); wound management devices;
drug-delivering vascular stents (e.g., a balloon-expanded
stents); other vascular devices (e.g., grafts, catheters, valves,
artificial hearts, heart assist devices); implantable defibrilla
tors; blood oxygenator devices (e.g., tubing, membranes);
membranes; biosensors; shunts for hydrocephalus; endo
scopic devices; infection control devices; dental devices (e.g.,
dental implants, fracture repair devices), urological devices
(e.g., penile, sphincter, urethral, bladder and renal devices,
and catheters); ophthalmic devices (e.g. intraocular coils/
screws); glaucoma drain shunts; synthetic prostheses (e.g.,
breast); intraocular lenses; respiratory, peripheral cardiovas
cular, spinal, neurological, dental, ear/nose/throat (e.g., ear
drainage tubes); renal devices; and dialysis (e.g., tubing,
membranes, grafts), urinary catheters, intravenous catheters,
small diameter grafts, vascular grafts, artificial lung catheters,
atrial septal defect closures, electro-stimulation leads for car
diac rhythm management (e.g., pacer leads), glucose sensors
(long-term and short-term), degradable coronary stents (e.g.,
degradable, non-degradable, peripheral), blood pressure and
stent graft catheters, birth control devices, prostate cancer
implants, bone repair/augmentation devices, breast implants,
cartilage repair devices, dental implants, implanted drug infu
sion tubes, intravitreal drug delivery devices, nerve regenera
tion conduits, oncological implants, electrostimulation leads,
pain management implants, spinal/orthopedic repair devices,
wound dressings, embolic protection filters, abdominal aortic
aneurysm grafts, heart valves (e.g., mechanical, polymeric,
tissue, percutaneous, carbon, sewing cuff), valve annuloplasty devices, mitral valve repair devices, vascular interven
tion devices, left ventricle assist devices, neuro-aneurysm
treatment coils, neurological catheters, left atrial appendage
filters, hemodialysis devices, catheter cuff, anastomotic clo
sures, vascular access catheters, cardiac sensors, uterine
bleeding patches, urological catheters/stents/implants, aneu
rysm exclusion devices, and neuropatches.
Examples of other suitable devices include, but are not
limited to, vena cava filters, urinary dialators, endoscopic

surgical tissue extractors, atherectomy catheters, clot extrac
tion catheters, coronary guidewires, drug infusion catheters,
esophageal stents, circulatory support systems, angiographic
catheters, coronary and peripheral guidewires, hemodialysis
catheters, neurovascular balloon catheters, tympanostomy
vent tubes, cerebro-spinal fluid shunts, defibrillator leads,
percutaneous closure devices, drainage tubes, thoracic cavity
suction drainage catheters, electrophysiology catheters,
stroke therapy catheters, abscess drainage catheters, biliary
drainage products, dialysis catheters, central venous access
catheters, and parental feeding catheters.
Also provided are methods of treating a patient in need of
a medical implant. The methods involve selecting a medical
implant where the implant comprises a surface having nano
tubes capable o f enhancing or promoting cell growth or pro
liferation and placing the implant into the patient. In this
embodiment, the term “selecting” means, for example, pur
chasing, choosing, or providing the implant rather than pre
paring the implant.
By varying the time of electrochemical etching of the
native material surface, the implant surface can be engineered
to provide the desired local nano structured surface. By using
point and cylindrical electrodes at the proper locations, dis
tances, voltages, and times, tubular nanostructures can also be
etched on the surface of interior features such as holes and
sharp depressions of regular and irregular shape, interior
sharp corners and concave features, exterior features such as
protrusions o f regular and irregular shape, exterior sharp cor
ners and convex features, all typically found on the surface of
orthopedic implants or other implantable devices where such
tubular nanostructures are desired.
Advantageously, second metals or combinations o f metals
are used to coat the surface or are otherwise incorporated into
the surface to alter its ability to support mammalian cell or
microbial cell growth.
Nanotubes for Drug Delivery
In another embodiment of the invention, an implant that
has undergone electrochemical etching is used to deliver
therapeutic or prophylactic agents in vivo. More specifically,
the titanium nanotubes on the implant surface act as carriers
and reservoirs to deliver drugs to certain locations of the body
over various predetermined time periods.
The invention provides a simple means for delivering bio
logically active agents (e.g., small compounds, nucleic acid
molecules, polypeptides) using a nanotube modified implant
or medical device. The nanotube modified implant is deliv
ered to a subject and the biologically active agent is eluted
from the composition in situ.
The agents may be adsorbed onto and incorporated into the
biodegradable nanostructure surface, by dipping the implant
into a solution or dispersion containing the agents and/or
additives, orby othermeans recognized by those skilled in the
art. In some embodiments, the nanostructure will release the
adsorbed biological agents and additives in a time-controlled
fashion. In this way, the therapeutic advantages imparted by
the addition of biological agents and additives may be con
tinued for an extended period of time.
The nanotube modified implant is capable of delivering an
agent for the treatment of a disease or disorder that requires
controlled and/or localized drug delivery over some period of
time (e.g., 1, 3, 5, 7 days; 2, 3,4 weeks; 1,2,3, 6,12 months).
Desirably, the nanotube modified implant comprises an effec
tive amount of one or more antibiotics, growth factors that
promote cell growth, statins that promote bone growth, small
molecules, or cartilage or bone repair agents. Preferably, the
nanotube modified implant comprises at least about 1 pg, 25
pg, 50 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 mg, 5 mg, 10 mg,
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25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 250 mg, 300 mg, 400
mg, or 500 mg of an agent (e.g., an antibiotic). In another
embodiment, the composition releases at least about 1 pg, 25
pg, 50 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 mg, 5 mg, 10 mg,
25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 250 mg, 300 mg, 400
mg, or 500 mg of an agent (e.g., an antibiotic) over the course
of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 21, 28, or 35
days. In still another embodiment, the composition comprises
at least about 1 pg, 25 pg, 50 pg, 100 pg, 250 pg, 500 pg, 750
pg, 1 mg, 5 mg, lOmg, 25 mg, 50mg, 75 mg, 100mg, 200mg,
250 mg, 300 mg, 400 mg, or 500 mg of an agent (e.g., an
antibiotic) per cm3.
Anti-Inflammatories
In other embodiments, a nanotube modified implant is used
to deliver an anti-inflammatory agent. Such anti-inflamma
tory agents include, but are not limited to, Alclofenac;
Alclometasone Dipropionate; Algestone Acetonide; Alpha
Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen;
Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen;
Benzydamine Hydrochloride; Bromelains; Broperamole;
Budesonide; Carprofen; Cicloprofen; Ciclsporin, Cintazone;
Cliprofen; Clobetasol Propionate; Clobetasone Butyrate;
Clopirac; Cloticasone Propionate; Cormethasone Acetate;
Cortodoxone; Curcumin; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac
Potassium; Diclofenac Sodium; Diflorasone Diacetate;
Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone;
Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab;
Enolicam Sodium; Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclofenac; Fenclorac; Fendosal;
Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic
Acid; Flumizole; Flunisolide Acetate; Flunixin; Flunixin
Meglumine; Fluocortin Butyl; Fluorometholone Acetate;
Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propi
onate; Furaprofen; Furobufen; Halcinonide; Halobetasol Pro
pionate; Halopredone Acetate; Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin;
Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride; Lornoxicam; Loteprednol Etabonate;
Meclofenamate Sodium; Meclofenamic Acid; Meclorisone
Dibutyrate; Mefenamic Acid; Mesalamine; Meseclazone;
Methylprednisolone Suleptanate; Momiflumate; Nabumetone; Naproxen; Naproxen Sodium; Naproxol; Nimazone;
Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin;
Oxyphenbutazone; Paranyline Hydrochloride; Pentosan
Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pirfenidone; Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate; Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate; Rimexolone;
Romazarit; Salcolex; Salnacedin; Salsalate; Sanguinarium
Chloride; Seclazone; Sermetacin; Sudoxicam; Sulindac;
Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone;
Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide;
Tetrydamine; Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate; Zidometacin; and
Zomepirac Sodium.
Growth Factors
In other embodiments, a nanotube modified implant is used
to deliver a growth factor. Growth factors are typically
polypeptides or fragments thereof that support the survival,
growth, or differentiation of a cell. A nanotube modified
implant described herein can be used to deliver virtually any
growth factor known in the art. Such growth factors include
but are not limited to angiopoietin, acidic fibroblast growth
factors (aFGF) (GenBank Accession No. NP_149127) and

basic FGF (GenBank Accession No. AAA52448), bonemorphogenic protein (BMP)(GenBank Accession No.
BAD92827), vascular endothelial growth factor (VEGF)
(GenBank Accession No. AAA35789 or NP_001020539),
epidermal growth factor (EGF)(GenBank Accession No.
NP_001954), transforming growth factor a (TGF-a) (Gen
Bank Accession No. NP_003227) and transforming growth
factor (3 (TFG-|3) (GenBank Accession No. 1109243A),
platelet-derived endothelial cell growth factor (PD-ECGF)
(GenBank Accession No. NP_001944), platelet-derived
growth factor (PDGF)(GenBank Accession No. 1109245A),
tumor necrosis factor a (TNF-a)(GenBank Accession No.
CAA26669), hepatocyte growth factor (HGF)(GenBank
Accession No. BAA14348), insulin like growth factor (IGF)
(GenBank Accession No. P08833), erythropoietin (GenBank
Accession No. P01588), colony stimulating factor (CSF),
macrophage-CSF (M-CSF)(GenBank Accession No.
AAB59527), granulocyte/macrophage CSF (GM-CSF)
(GenBank Accession No. NP_000749) and nitric oxide syn
thase (NOS)(GenBank Accession No. AAA36365). In one
preferred embodiment, the growth factor is BMP. In another
embodiment, the agent is a statin that promotes bone growth.
Exemplary statins include but are not limited to simvastatin,
atorvastatin (Lipitor), cerivastatim, fluvastatin, lovastatin,
and pravastatin.
Antimicrobial Agents
Staphylococcus aureus, staphylococcus epidermidis, and
Pseudomonas aeruginosa are pathogens that are commonly
present at musculoskeletal wound sites. S. aureus is often
associated with prosthetic joint infection. The invention pro
vides nanotube modified orthopedic implants useful in treat
ing or preventing infection at a site of trauma. Any antimicro
bial agent known in the art can be used in the nanotube
modified implants of the invention at concentrations gener
ally used for such agents.
Antimicrobial agents useful in nanotube compositions of
the invention include but are not limited to antibacterials,
antifungals, and antivirals. An antimicrobial agent as used
herein is an agent which reduces or stabilizes the survival,
growth, or proliferation of a pathogen. Antimicrobial agents
include but are not limited to Aztreonam; Chlorhexidine Glu
conate; Imidurea; Lycetamine; Nibroxane; Pirazmonam
Sodium; Propionic Acid; Pyrithione Sodium; Sanguinarium
Chloride; Tigemonam Dicholine; Acedapsone; Acetosulfone
Sodium; Alamecin; Alexidine; Amdinocillin; Amdinocillin
Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate;
Amikacin; Amikacin Sulfate; Aminosalicylic acid; Ami
nosalicylate sodium; Amoxicillin; Amphomycin; Ampicillin;
Ampicillin Sodium; Apalcillin Sodium; Apramycin; Aspartocin; Astromicin Sulfate; Avilamycin; Avoparcin; Azithro
mycin; Azlocillin; Azlocillin Sodium; Bacampicillin Hydro
chloride; Bacitracin; Bacitracin Methylene Disalicylate;
Bacitracin Zinc; Bambermycins; Benzoylpas Calcium;
Berythromycin; Betamicin Sulfate; Biapenem; Biniramycin;
Biphenamine Hydrochloride; Bispyrithione Magsulfex;
Butikacin; Butirosin Sulfate; Capreomycin Sulfate; Carbadox; Carbenicillin Disodium; Carbenicillin Indanyl Sodium;
Carbenicillin Phenyl Sodium; Carbenicillin Potassium;
Carumonam Sodium; Cefaclor; Cefadroxil; Cefamandole;
Cefamandole Nafate; Cefamandole Sodium; Cefaparole;
Cefatrizine; Cefazaflur Sodium; Cefazolin; Cefazolin
Sodium; Cefbuperazone; Cefdinir; Cefepime; Cefepime
Hydrochloride; Cefetecol; Cefixime; Cefinenoxime Hydro
chloride; Cefmetazole; Cefmetazole Sodium; Cefonicid
Monosodium; Cefonicid Sodium; Cefoperazone Sodium;
Ceforanide; Cefotaxime Sodium; Cefotetan; Cefotetan Diso
dium; Cefotiam Hydrochloride; Cefoxitin; Cefoxitin

5

10

15

20

25

30

35

40

45

50

55

60

65

US 9,376,759 B2

17

18

Sodium; Cefpimizole; Cefpimizole Sodium; Cefpiramide;
Cefpiramide Sodium; Cefpirome Sulfate; Cefpodoxime
Proxetil; Cefprozil; Cefroxadine; Cefsulodin Sodium;
Ceftazidime; Ceftibuten; Ceftizoxime Sodium; Ceftriaxone
Sodium; Cefuroxime; Cefuroxime Axetil; Cefuroxime Pivoxetil; Cefuroxime Sodium; Cephacetrile Sodium; Cephal
exin; Cephalexin Hydrochloride, Cephaloglycin; Cephaloridine; Cephalothin Sodium; Cephapirin Sodium; Cephradine;
Cetocycline Hydrochloride; Cetophenicol; Chlorampheni
col; Chloramphenicol Palmitate; Chloramphenicol Pantoth
enate Complex; Chloramphenicol Sodium Succinate; Chlorhexidine Phosphanilate; Chloroxylenol; Chlortetracycline
Bisulfate; Chlortetracycline Hydrochloride; Cinoxacin;
Ciprofloxacin; Ciprofloxacin Hydrochloride; Cirolemycin;
Clarithromycin; Clinafloxacin Hydrochloride; Clindamycin;
Clindamycin Hydrochloride; Clindamycin Palmitate Hydro
chloride; Clindamycin Phosphate; Clofazimine; Cloxacillin
Benzathine; Cloxacillin Sodium; Cloxyquin; Colistimethate
Sodium; Colistin Sulfate; Coumermycin; Coumermycin
Sodium; Curcumin; Cyclacillin; Cycloserine; Dalfopristin;
Dapsone; Daptomycin; Demeclocycline; Demeclocycline
Hydrochloride; Demecycline; Denofungin; Diaveridine;
Dicloxacillin; Dicloxacillin Sodium; Dihydro streptomycin
Sulfate; Dipyrithione; Dirithromycin; Doxycycline; Doxycycline Calcium; Doxycycline Fosfatex; Doxycycline Hyclate;
Droxacin Sodium; Enoxacin; Epicillin; Epitetracycline
Hydrochloride; Erythromycin; Erythromycin Acistrate;
Erythromycin Estolate; Erythromycin Ethylsuccinate; Eryth
romycin Gluceptate; Erythromycin Lactobionate; Erythro
mycin Propionate; Erythromycin Stearate; Ethambutol
Hydrochloride; Ethionamide; Fleroxacin; Floxacillin; Fludalanine;
Flumequine;
Fosfomycin;
Fosfomycin
Tromethamine; Fumoxicillin; Furazolium Chloride; Furazolium Tartrate; Fusidate Sodium; Fusidic Acid; Gentamicin
Sulfate; Gloximonam; Gramicidin; Haloprogin; Hetacillin;
Hetacillin Potassium; Hexedine; Ibafloxacin; Imipenem; Isoconazole; Isepamicin; Isoniazid; Josamycin; Kanamycin Sul
fate; Kitasamycin; Levofuraltadone; Levopropylcillin Potas
sium;
Lexithromycin;
Lincomycin;
Lincomycin
Hydrochloride; Lomefloxacin; Lomefloxacin Hydrochlo
ride; Lomefloxacin Mesylate; Loracarbef; Mafenide; Meclocycline; Meclocycline Sulfosalicylate; Megalomicin Potas
sium Phosphate; Mequidox; Meropenem; Methacycline;
Methacycline Hydrochloride; Methenamine; Methenamine
Hippurate; Methenamine Mandelate; Methicillin Sodium;
Metioprim; Metronidazole Hydrochloride; Metronidazole
Phosphate; Mezlocillin; Mezlocillin Sodium; Minocycline;
Minocycline Hydrochloride; Mirincamycin lydrochloride;
Monensin; Monensin Sodium; Nafcillin Sodium; Nalidixate
Sodium; Nalidixic Acid; Natamycin; Nebramycin; Neomy
cin Palmitate; Neomycin Sulfate; Neomycin Undecylenate;
Netilmicin Sulfate; Neutramycin; Nifuradene; Nifuraldezone; Nifuratel; Nifuratrone; Nifurdazil; Nifurimide;
Nifurpirinol; Nifurquinazol; Nifurthiazole; Nitrocycline;
Nitrofurantoin; Nitromide; Norfloxacin; Novobiocin
Sodium; Ofloxacin; Ormetoprim; Oxacillin Sodium; Oximonam; Oximonam Sodium; Oxolinic Acid; Oxytetracycline; Oxytetracycline Calcium; Oxytetracycline Hydrochlo
ride;
Paldimycin;
Parachlorophenol;
Paulomycin;
Pefloxacin; Pefloxacin Mesylate; Penamecillin; Penicillin G
Benzathine; Penicillin G Potassium; Penicillin G Procaine;
Penicillin G Sodium; Penicillin V; Penicillin V Benzathine;
Penicillin V Hydrabamine; Penicillin V Potassium; Pentizidone Sodium; Phenyl Aminosalicylate; Piperacillin Sodium;
Pirbenicillin Sodium; Piridicillin Sodium; Pirlimycin Hydro
chloride; Pivampicillin Hydrochloride; Pivampicillin Pamo
ate; Pivampicillin Probenate; Polymyxin B Sulfate; Porfiro-

mycin; Propikacin; Pyrazinamide; Pyrithione Zinc;
Quindecamine Acetate; Quinupristin; Racephenicol;
Ramoplanin; Ranimycin; Relomycin; Repromicin; Rifabu
tin; Rifametane; Rifamexil; Rifamide; Rifampin; Rifapentine; Rifaximin; Rolitetracycline; Rolitetracycline Nitrate;
Rosaramicin; Rosaramicin Butyrate; Rosaramicin Propi
onate; Rosaramicin Sodium Phosphate; Rosaramicin Stear
ate; Rosoxacil; Roxarsone; Roxithromycin; Sancycline; Sanfetrinem Sodium; Sarmoxicillin; Sarpicillin; Scopafungin;
Sisomicin; Sisomicin Sulfate; Sparfloxacin; Spectinomycin
Hydrochloride; Spiramycin; Stallimycin Hydrochloride;
Steffimycin; Streptomycin Sulfate; Streptonicozid; Sulfabenz: Sulfabenzamide; Sulfacetamide; Sulfacetamide
Sodium; Sulfacytine; Sulfadiazine; Sulfadiazine Sodium;
Sulfadoxine; Sulfalene; Sulfamerazine; Sulfameter; Sul
famethazine; Sulfamethizole; Sulfamethoxazole; Sulfamonomethoxine; Sulfamoxole; SulfanilateZinc; Sulfanitran;
Sulfasalazine; Sulfasomizole; Sulfathiazole; Sulfazamet;
Sulfisoxazole; Sulfisoxazole Acetyl; Sulfisoxazole Diolamine; Sulfomyxin; Sulopenem; Sultamicillin; Suncillin
Sodium; Talampicillin Hydrochloride; Teicoplanin; Temafloxacin Hydrochloride; Temocillin; Tetracycline; Tetracy
cline Hydrochloride; Tetracycline Phosphate Complex;
Tetroxoprim; Thiamphenicol; Thiphencillin Potassium;
Ticarcillin Cresyl Sodium: Ticarcillin Disodium; Ticarcillin
Monosodium; Ticlatone; Tiodonium Chloride; Tobramycin;
Tobramycin Sulfate; Tosufloxacin; Trimethoprim; Trimetho
prim Sulfate; Trisulfapyrimidines; Troleandomycin; Trospectomycin Sulfate; Tyrothricin; Vancomycin; Vancomycin
Hydrochloride; Virginiamycin; Zorbamycin; Difloxacin
Hydrochloride; Lauryl Isoquinolinium Bromide; Moxalactam Disodium; Ornidazole; Pentisomicin; and Sarafloxacin
Hydrochloride.
Delivery of Nanotube Compositions
Nanotube modified implants can be delivered by any
method known to the skilled artisan. In one approach, a nano
tube modified implant is surgically implanted at a site where
a dental implant, orthopedic implant, cardiovascular implant,
neurological implant, neurovascular implant, gastrointestinal
implant, muscular implant, cochlear implant, and ocular
implant is required. If desired, the nanotube modified implant
is loaded with one or more antibiotics or other biologically
active agents by a clinician. In one embodiment, a biologi
cally active agent is loaded into nanotube by placing the
implant into a vacuum chamber that also has the capability of
depositing the agents onto the surface. Devices for vacuum
depositing compounds on surfaces are known in the art. As
the vacuum is slowly decreased toward ambient pressure the
agent is deposited into the nanotube.
Kits
The invention provides kits that include nanotube modified
implants. In one embodiment, the kit includes a nano tube
modified implant containing a therapeutic or prophylactic
agent that that prevents or treats infection (e.g., an antimicro
bial agent) or that promotes healing (e.g., growth factor, anti
inflammatory, clot promoting agent, anti-thrombotic). In
some embodiments, the kit comprises a sterile container
which contains a nanotube modified implant; such containers
can be boxes, ampoules, bottles, vials, tubes, bags, pouches,
blister-packs, or other suitable container forms known in the
art. Such containers can be made of plastic, glass, laminated
paper, metal foil, or other materials suitable for holding medi
caments.
If desired a nanotube modified implant of the invention is
provided together with instructions for using it in a prophy
lactic or therapeutic method described herein. The instruc
tions will generally include information about the use of the
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composition for the treatment of a trauma, infection or related
disease in a subject in need thereof. The instructions may be
printed directly on the container (when present), or as a label
applied to the container, or as a separate sheet, pamphlet,
card, or folder supplied in or with the container.
Electrochemical Etching Device and System
The invention provides a device for selectively modifying
a surface to generate nano tubes. In one embodiment, the
device features one or more cathodes (e.g., graphite), one or
more anodes (e.g., graphite) and a titanium or titanium alloy
surface in an electrolyte solution, wherein the anode is in
proximity to the surface; at least one power supply in electri
cal communication with the cathode and anode(s), such that
when voltage is applied in the presence of an electrolyte
solution nanotubes are formed on the surface; and a support
for positioning the cathode and one or more anodes relative to
the surface. In one embodiment, the cathode and/or anodes
are point or cylindrical electrodes that can be positioned
relative to selected sites on the surface. In another embodi
ment, the distance of the cathode and/or anodes relative to the
surface is varied, the voltage applied is varied, and the dura
tion for which the voltage is applied is varied. The voltage,
time, and distances are selected to form nanotubes whose
length and/or diameter differs between sites on the surface.
The invention provides an automated system for etching a
titanium or titanium alloy surface to form nanotubes at one or
more selected sites on the surface. In one embodiment, the
device features a support for positioning the cathode and one
or more anodes relative to a titanium or titanium alloy surface;
a cathode and one or more anodes in electrical communica
tion with said power supply; wherein when voltage is applied
in the presence of an electrolyte solution nanotubes are
formed at selected sites on the surface; and a control device
for detecting the electrical resistance and current within the
system, wherein the control device is configured to controllably adjust the distances, voltages, and times used to form
nanotubes at selected sites on the surface.
If the etching electrical current is measured to very high
precision over time the current within the system can serve as
a feedback signal to the automated machine control system
correlating with one or more of the following: nanotube diam
eter, nanotube length, projected area of titanium removed
between nanotubes and within their inner diameter, and vol
ume of titanium removed from between nanotubes and within
their inner diameter. This feedback signal automatically alters
electrode position, distance from the surface, voltage, and the
time for which the voltage is applied to achieve nanotubes
having the desired dimensions, mechanical stiffness, or other
properties.
The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to make and use the assay, screening, and
therapeutic methods of the invention, and are not intended to
limit the scope of what the inventors regard as their invention.

enhancing cell growth and adhesion on titanium surfaces.
Methods were developed to fabricate the nanotubular struc
tures on titanium surfaces.
T i0 2 nanotubes were synthesized from titanium substrates
using anodization. The fabrication process used an etching
set-up involving a Ti anode, a counter electrode; electrolyte,
and a DC power source (FIG. 1). The substrates for nanotube
etching were flat, 2 cmx3 cm and 0.25 mm thick, andpolished
with 0.06 mm colloidal S i0 2. Prior to nanotube etching, the
substrates were sequentially sonicated in acetone, isopropyl
alcohol, and methanol, then rinsed with deionized water, and
dried in an N2 stream. The experimental setup consisted of a
two-electrode arrangement. Four different metals (platinum,
stainless steel, copper, and graphite) were used as the counter
electrodes for four different sets of anodizations. The spacing
between the substrates and the counter electrode was approxi
mately 25 mm. The anodization was carried out at room
temperature. The electrolyte was 0.2 wt % solution of NH4F
in 49 ml ethylene glycol and 1 ml deionized water (49 mL
ethylene glycol, 1 mL water, and 0.33 grams of ammonium
fluoride). The electrolyte used is benign compared to previ
ously reported electrolytes of hydrofluoric acid and nitric
acid. The innocuous etching electrolyte (NF14F and ethylene
glycol rather than F1F), makes the process considerably safer,
cheaper, and easier to maintain by eliminating the need for
costly specialized environmental containment and disposal
safeguards. Additionally, it ensures that any residual chemical
etchant that might cling to the product surface would be
essentially benign. A constant 60 V DC was used for all
experiments. After anodization, the samples were rinsed with
deionized water and dried in a N2 stream.
Nanotubes formed by different counter electrodes were
analyzed by scanning electron microscopy (SEM) and
energy-dispersive X-ray spectroscopy (EDS) (FIGS. 2A-2B).
SEM analysis showed nanotubes were formed when commer
cially pure (cp) Ti was used as anode and Pt as counter
electrode (FIG. 2A). As shown by the EDS analysis, T i0 2
nanotubes using Pt as counter electrode were pure with no
traces of other elements. SEM analysis showed nanotubes
were formed when cp Ti was used as anode and stainless steel
as the counter electrode (FIG. 2B). As shown by the EDS
analysis, T i0 2 nanotubes using stainless steel as counter elec
trode have some traces of Fe and Cr and are not pure. SEM
analysis showed nanotubes were formed when cp Ti was used
as anode and Cu as counter electrode (FIG. 2C). As shown by
the EDS analysis, T i0 2 nanotubes formed using copper as the
counter electrode are pure with no traces of Cu element. SEM
analysis showed nanotubes were formed when cp Ti was used
as anode and graphite as counter electrode (FIG. 2D). As
shown by the EDS analysis, T i0 2 nanotubes using graphite as
counter electrode are pure with no traces of other elements.
Taking into consideration the fact that Pt is an expensive
metal, substituting Pt in the counter electrode has the poten
tial to reduce the cost of nanotube fabrication. Moreover,
materials other than Pt may provide additional advantages.
For example, graphite can also be easily shaped into a point
electrode, thus, allowing the use of multiple graphite counter
electrodes. Additionally, replacing a single Pt electrode with
multiple and individually addressable graphite electrodes sig
nificantly lowers the operating cost of the process (over
5000x electrode price differential) while increasing versatil
ity.
Due to the very high cost of platinum and the undesirable
effects of stainless steel and copper electrodes, graphite was
chosen for all future work. In a typical apparatus whereby
uniform nanotubular structures are produced on a titanium
specimen, the platinum specimen is connected to +60 VDC
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Ti Nanotube Fabrication Using Anodization
Nanotubes were fabricated onto/into the surface of pure
and Ti6A14V titanium sheets and Ti6A14V ELI orthopedic
hardware by anodization. Titanium and titanium alloy sur
faces comprising nanotubes were studied for the purpose of
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and the graphite electrode is connected to electrical ground
(FIG. 3). The platinum and graphite electrode are placed in
the ammonium fluoride electrolyte and the circuit is ener
gized. Typical nanotubular structures were produced under
these fabrication conditions using graphite electrodes (FIG.
4). Additionally, under this apparatus configuration, repro
ducible results with quantifiable relationships among anod
ization time, voltage, electrode standoff distance and geomet
ric complexity o f the implant surface were obtained. Surface
morphologies ranged from continuous and porous to multiple
and independent vertical nanotubes (FIGS. 5A and 5B). Voltage/time data indicate aspect ratio & tube wall conditions can
be controlled (Table 1).

Water droplets were placed on bare Ti foil, pure TNT, and
alloy TNT in as-synthesized and annealed conditions (FIG.
7A). Images o f droplets on the surfaces were captured five to
ten times for each case and the corresponding contact angles
calculated. A digital image analysis algorithm was developed
to obtain contact angles, contact radii, and center-heights of
the droplets on the nano tube surfaces.
Data were plotted to show the trend of the contact angle
variation (FIG. 7B). Three observations were made from the
wettability experiments. The first was the difference between
the contact angles of the bare pure and bare alloy titanium
foils. In the case of pure titanium, the contact angles were
larger than the alloy. Second, it was found that the creation of
TNT structures made the surface more hydrophilic. In all
cases after the anodization process, the droplet contact angles
decreased in the range of 55-70% compared to the contact
angles of each bare foil. The third phenomenon was that the
annealing made the TNT surfaces super-hydrophilic. In gen
eral, annealing metal generates a hydrophobic surface. Sur
prisingly and unexpectedly, annealing produced super-hydro
philic surfaces. The water droplet contact angles on the
annealed TNT surfaces decreased 40-56% compared to the
as-anodized TNT surface cases. The annealing resulted in
nanotubes of anatase causing super-hydrophilic surfaces to
be generated.
The effect of ageing of the TNT surfaces on wettability was
examined during and after three months (FIG. 8). Water drop
lets were placed on bare titanium, as-anodized TNT, and
annealed TNT after ageing. For the TNT surfaces, it was
found that the surface wettabilities changed from hydrophilic
to hydrophobic or from super-hydrophilic to hydrophilic after
ageing. All of the TNT surfaces had the same tendency and
the resulting water droplet contact angles are shown in Table
2.
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TABLE 1
Effect o f anodization time and voltaae on TiO-, nanotube lensth.
Time
Voltage

4 Hrs

8 Hrs

16 Hrs

20 V
40 V
60 V

589 nm
1,443 nm
5,493 nm

1,070 nm
4,530 nm
6,754 nm

1,388 nm
6,114 nm
10,075 nm

20

25

Thus, nanotubular structures were fabricated using inex
pensive graphite cylindrical rods (rod electrodes) and electri
cally insulating coated graphite rods leaving only the tip
uncoated (point electrodes) in place of expensive platinum
sheet electrodes. The nanotubular structures were fabricated
using a separation distance between the titanium and graphite
that can vary from close proximity to up to 100 mm, without
limitation. Ti nanotubes were quickly fabricated with increas
ing anodization voltage up to +60 VDC.
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Example 2
TABLE 2
Nanotube Annealing Increases Wettability of T i0 2
Nanotube Surfaces

Variation o f contact angle with respect to time
40

This study examined the effect of annealing and ageing on
the wettability of T i02 nano tube surfaces (TNT) fabricated by
anodization. The wettability of a surface is important in aque
ous cell growth since a hydrophobic (non-wettable) surface
will repel water and cause it to bead-up. Commercially pure
and grade-5 (Ti6A14V) titanium alloy foils were used to fab
ricate T i02 nanotubes. Post-anodization thermal treatment
was at 450° C. using a rapid thermal annealer. A heating/
cooling rate o f308° C./min was used, and the substrates were
annealed in air at 450° C. for 3 hours. The annealing treatment
resulted in phase transformation of nanotubes from amor
phous to crystalline anatase. Thermally treated surfaces were
analyzed by TEM and compared to surfaces without treat
ment (FIGS. 6A-6B). Thermally treated surfaces had
annealed T i02 nanotubes compared to surfaces without treat
ment, which had amorphous nanotubes.
Water droplets (one-microliter) were used to define the
wettability of the TNT surfaces by measuring the contact
angles. One-microliter of de-ionized (DI) water was slowly
deposited on the surfaces by a screw syringe. The experi
ments were repeated five times for each measurement. The
temperature and humidity were maintained at 24±0.5° C. and
21 ±1%, respectively. Priorto the experiments, droplet depo
sition was repeatedly tested to ensure that the water droplets
had consistent shapes.
During the experiment, a droplet was dynamically
recorded on an image capturing system via a CCD camera.

Contact angle (°)
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Pt

Pure
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Pure
Alloy
Pure
Alloy

0 day

22 day

51 day

92 day

10.76
14.59
24.62
32.39
82.52
67.07

21.85
19.45
28.25
37.97
74.63
54.84

23.39
31.56
34.05
42.23
78.66
73.48

26.94
44.12
42.47
80.35
81.24
56.80

The contact angle analyses were made 22, 51, and 92 days
after fabrication. The hydrophobicity increased at different
rates for each case, but all o f the water droplet contact angles
increased on the TNT structured surfaces. Data were plotted
to show the variation of contact angles for the cases of the
annealed and as-anodized TNT surfaces (FIG. 9A). Invari
ably, the results show that the surface hydrophobicity was
increased for all four cases.
T i0 2 has hydrophobic characteristics. Without being
bound to a particular theory, as time passed, the hydropho
bicity increased. The change in the wetting behavior of T i0 2
porous structures provides advantages in various applica
tions. For example, there is often high sensitivity to different
wetting characteristics that affect the biological responses of
protein adsorption, cell affinity or cell adhesion on a surface.
For bare titanium and alloy, wettability does not change as a
function of ageing (FIG. 9B). The measured contact angles of
droplets remained nearly unchanged for each case. Without
being bound to a particular theory, at the early stage, the
contact angles decreased a small amount due to the initial
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oxidation of the metal. Before the experiment, the initial
titanium foils were cleaned with ethanol and acetone. These
samples then became oxidized through exposure to the air. An
initial decrease of the contact angles was observed. However,
the wettabilities of the bare titanium foils remained constant
with respect to time after this initial change.
Thus, bare titanium foil is inherently hydrophobic, having
an approximately 60-80 degree contact angle. Untreated T i0 2
nanotube surfaces (as-anodized) were more hydrophilic than
titanium foil. Annealing T i02 nanotube surfaces by heat treat
ment further increased the hydrophilic property. However,
T i02 nanotube surface became more hydrophobic when aged
in air. These results indicate that where surface wettability is
an advantage, using the anodization process described herein
can grow nanotubes having this property. This process pro
vides a potential application for producing orthopedic
implants where the wettability characteristics of the surface
can be specified.

by 25 mm high and was not electrically connected. A second
3 mm graphite electrode was placed on the other side of the
specimen from the first electrode at a distance of 70 mm from
the specimen and was connected to electrical ground. Fabri
cation was allowed to continue for 97 minutes. Without being
bound to a particular theory, a portion of the total current
flowing from the positive to the ground electrode enters the
specimen on the side nearest the positive electrode. The cur
rent entering the specimen on the positive electrode side will
leave the specimen as it seeks the ground potential. This
leaving current will do so primarily on the ground electrode
side of the specimen, but a small portion of the leaving current
may leave at or near the sides of the specimen at some dis
tance from the positive electrode. Current does not leave the
specimen in the proximity of the positive electrode. There
fore, nanotube fabrication is inhibited on the side nearest the
positive electrode (FIG. 11).
To better understand the prior result, an experiment was
conducted where the position of the titanium specimen was
moved in relation to the arrangement of the electrodes (FIG.
12). The voltage was +60 VDC and the specimen was allowed
to electrically float. The fabrication duration was 60 minutes.
Without being bound to a particular theory, the maj ority of the
current flows directly from the positive to the negative elec
trode. However, the electrolyte has a relatively low electrical
conductivity owing to its chemical makeup. Therefore, a por
tion of the current emanating from the positive electrode
flows outward and enters the specimen primarily on one side.
Nanotube fabrication is inhibited over most of this proximal
side (FIG. 13). However, the current entering the specimen
leaves it on the opposing side and nanotube fabrication takes
place (FIG. 13).
As a further demonstration, a set-up was used where the
position of the titanium specimen was moved into close prox
imity to both electrodes (FIG. 14). The voltage was +60 VDC
and the fabrication duration was 30 minutes. Without being
bound to a particular theory, current enters the specimen near
the positive electrode inhibiting nanotube fabrication (FIG.
15). Current leaves the specimen on the opposing side of the
specimen and other locations on the electrode side that are
away from the positive electrode. All of the leaving current
fabricates nanotubes (FIG. 15).
From these results, using large graphite rod electrodes
(typically 3 mm in diameter) and placed relatively far from
the specimens (typically 6-12 mm away), it was appreciated
that if the graphite electrodes are made as smaller rods or
points and placed at a closer proximity, inhibiting the fabri
cation of nanotubes locally on the specimen surface is
attained at a higher resolution of placement. It was also appre
ciated that if after some duration of nanotube fabrication and
inhibition time, the polarity of the positive graphite electrode
is made negative while at the same time the specimen polarity
is made positive, then nanotubes continue to be fabricated
uniformly over the entire surface providing one or more
regions of relatively long nanotubes and one or more regions
of shorter nanotubes, based on the total time and current flow
direction of each region. Each region corresponds to one or
more graphite electrodes (e.g., an array of electrodes). Spe
cialized physical locating equipment and electrical voltage
control systems that are in common commercial use can be
used to achieve this type of system.
In one embodiment, the automated system comprises an
automated supporting system to hold the titanium implant
(FIG. 16). The automated supporting system can support the
implant from the top or can be a cradle-like structure from the
bottom. In either case, the support provides electrical contact
with the implant to form one side of the electrochemical
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Nanotube Growth Inhibition with Multiple
Electrodes
Using conventional electrochemical etching, nanotubular
structures are fabricated on titanium surfaces by anodization.
Without being bound to a particular theory, when current is
applied, in the electrochemical etching apparatus an electric
field emanates from a sheet electrode perpendicular to the
surface of that sheet at all locations and traverse the electro
lyte to the titanium specimen. The field lines enter the tita
nium specimen, regardless of shape, perpendicular to the
localized surface at all locations on the specimen. Without
being bound to a particular theory, the uniformity of these
field lines at the specimen (not at the electrode) produces the
fabricated nanotubular structures.
Again, without being bound to a particular theory, if the
electrode is a cylindrical rod or point the field lines will
emanate from that rod or point in a more concentrated man
ner, but will expand toward the much larger titanium speci
men and enter that specimen as described above. If the elec
trode is extremely close to the specimen, the field lines may
lack complete uniformity as they enter the specimen.
Nanotubular structures are fabricated on the specimen
where the voltage potential of the specimen is higher than
surrounding electrodes. This is defined as “current leaving”
the specimen—that is charge is moving from a more positive
voltage to a lower voltage at any location on the titanium
specimen. If however, “current enters” the titanium specimen
at any location, nanotube fabrication is inhibited. Underthese
specified fabrication conditions, the specimen may or may
not be electrically connected to the electrochemical etching
circuitry. The specimen may be allowed to electrically “float”
(not be connected to the circuit) without imposing a particular
voltage.
This innovation provides a method for locally inhibiting
nanotube etching. If an electrode rod or point is placed in
immediate proximity to the specimen surface, the electric
field emanating from that electrode may not disperse to the
entire specimen if there are other electrodes in close proxim
ity at other voltage potentials (FIG. 10). Here, the titanium
specimen is allowed to electrically float (it is not connected to
the circuit).
A positive graphite rod electrode 3 mm diameter was
placed 6 mm from the titanium specimen. The graphite elec
trode was connected to +60 VDC. The portion of the titanium
sheet specimen immersed in the electrolyte was 44 mm wide
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etching cell. The bottom structure can be multiple indepen
dently moved pins with the locations based on the implant
being processed. The geometric descriptions of implants are
contained in common computer aided design (CAD) systems
where the shape and extent of the surface is expressed math
ematically as a series of 3-D coordinates. Knowing the
implant to be processed, the system positions the supporting
pins appropriately. The pins may be moved by any means of
electromechanical actuation such as a ball screw or pneu
matic actuation. The supports are electrically insulated except
for the tip(s) which contact the implant as shown. These
supports are electrically common forming the anode side of
the circuit. Again, knowing the shape of the implant from the
CAD (or other) representation the individually addressable
point etching electrodes are positioned and energized. Based
on the nanotube dimensions desired at each particular loca
tion the voltage, etch time, and standoff distance is calculated
and automatically applied until the desired nanosurface is
produced (see, e.g., Table 1)
In additional and further embodiments, the etching current
of each electrode vs time is used to produce the desired
surface (FIG. 29). As the nano tubes form, the metal surface
becomes more porous as material is removed. Without being
bound to a particular theory, this results in a progressively
higher surface electrical resistance which, for each individu
ally addressable voltage, results in a decreasing etching cur
rent. The feedback signal can be used to individually halt
etching for each electrode and/or to change the voltage and/or
distance of each electrode based on the rate of change of the
etching current. The fully implemented automated system
may have many individual electrodes (e.g., an array of elec
trodes), not all of which are used for a specific implant.
Additionally, a system may have multiple implementations of
the schematic to simultaneously process multiple implants of
the same or different geometries.
Thus, a prescribed surface nanomorphology can be
achieved by actively locating multiple point or cylindrical
electrodes at prescribed distances, voltages, and times at dif
ferent locations on the surface of the implant. Additionally, by
using multiple graphite electrodes, and by selecting the volt
age of each electrode and the titanium, nanotube fabrication
can be allowed in selected regions of the titanium and inhib
ited in other selected regions of the titanium. These results can
be further extended to include varying both voltage and time
of each of the multiple electrodes (e.g., an array of electrodes)
to fabricate nanotubular structures of selected varying
lengths.

MC3T3-E1 cells were seeded onto the experimental substrate
of interest and were placed on a 30-well polystyrene plate and
stored in a 37° C. C 0 2 incubator for 24, 48 and 72 hrs to
observe the cell morphology and count the number of cells
attached as a function of incubation time. Samples of com
mercially pure Ti (cp Grade 2) and Ti6A14V (Grade 5), with
and without nanotubes were used to investigate the effect of
nano tubes on adhesion, and cell density of osteoblasts. These
two types of samples were chose based on the strong estab
lishment of Ti implants in orthopedics and their preferred
mechanical and biological properties.
A field-emission SEM was used for the morphological
characterization of the substrates. The length of the nanotubes
was determined from cross-section images. EDS chemical
composition data were collected to investigate the composi
tion of individual nanotubes and to confirm alloy nanotube
composition characteristics ofTi, Al, andV. Further morpho
logical and structural characterization of the T i0 2 nanostruc
tures were carried out with a TEM operated at 200 keV. After
evaluating the cell density and adhesion on T i0 2 nanotubes,
cell counts were conducted. By rapid rinsing with a phosphate
buffered saline (PBS) solution and fixation of the cells (de
scribed below) and immediate SEM imaging of the substrate,
only the attached cells were counted toward the cell density.
The high-resolution imaging gave the capability of distin
guishing between non-flat and well-spread flat cells and the
rinsing followed by rapid fixation removed the non-adherent
cells, resulting in a more accurate cell count assay. The num
ber of cells in an SEM image was counted by software. Five
random fields were counted per substrate and all experiments
were run in triplicate, repeated at least three times. The cell
count variability was ±5 cells/mm2. The mean numbers of
total attached cells were calculated from the total cell number
counted from 5 random square areas (1.Oxl.O mm2) of each
18 different substrates. The mean numbers of attached cells
on the surfaces of the control and nanotube covered samples
were compared for 24, 48 and 72 hrs of incubation.
For the FIB and SEM investigations, the cells were fixed on
the nanotube substrates. After 72 hrs of culture the medium
was replaced with 10 ml of 90% ethanol and after 10 min the
ethanol was pipetted out and the substrates were left to air dry
at 37° C. for 15 min. Substrates with fixed cells were inserted
into the specimen chamber of a FIB (Flitachi SA-2000). The
rough milling conditions to open a trench in the cell, used ion
currents of 5 to 7 nA at 30 kV. Lower beam currents of 100 to
670 pA were used to polish the cross section. Beam dwell
time for milling was 3 ps.
The density of MC3T3 cells after up to 72 hrs of incubation
on T i0 2 nano tubes with varying crystallinity and anodization
duration was measured. The density of adhered cells on amor
phous and crystalline T i0 2 nanotube surfaces was compared
with control bare surfaces for both cp and alloy substrates
(FIG. 17). On the bare control cp-Ti substrate, cell density
increased from 40 cells/mm2 after 24 hrs to 300 cells/mm2
after 72 hrs of incubation. The presence of nanotubes
enhanced cell density from 80 cells/mm2 after 24 hrs to 900
cells/mm2 after 72 hrs of incubation. In the case of annealed
cp-Ti02 nanotubes the cell density increased from 300 cells/
mm2 after 24 hrs to 2500 cells/mm2 after 72 hrs of incubation.
These results show that annealed nanotubes enhanced cell
density from 900 cells/mm2 in amorphous (ω-anodized)
nanotubes to 2500 cells/mm2 in annealed nanotubes after 72
hrs of incubation. In addition, on the bare control Ti6A14V
substrate cell density increased from 12 cells/mm2 after 24
hrs to 200 cells/mm2 after 72 hrs of incubation. However, the
results indicate that nanotube morphology enhanced cell den
sity from 40 cells/mm2 after 24 hrs to 800 cells/mm2 after 72
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Osteoblast Growth and Environment on Nanotube
Surfaces
In vitro experiments were conducted to investigate cell
density of MC3T3-E1 mouse osteoblasts (CRL-2593, sub
clone 4, ATCC USA). An aliquot of cells (1 ml) was mixed
with alpha minimum essential medium (a-MEM, 10 ml;
Invitrogen, USA) with 10 vol. % fetal bovine serum (FBS;
Invitrogen, USA) and 1 vol. % penicillin-streptomycin (PS;
Invitrogen, USA). The cell suspension was placed in a cell
culture dish and incubated at 37° C. and 5 vol. % C 0 2 envi
ronment. The concentration of the MC3T3-E1 osteoblastic
cells was checked under an optical microscope every 24 hrs
until it reached its saturation point of approximately 3000
cells/mm2 after 72 hrs of incubation. When the cells reached
their confluent point they were ready to be subcultured on
T i02 nanotube substrates or bare control substrates. The
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hrs of incubation. This enhanced cell density is in agreement
with the results on cp-Ti and cp-Ti02 nanotubes.
However, the total cell density in the control Ti6A14V and
alloyed-Ti02 nanotubes was slightly lower for all incubation
periods, in comparison to the total cell density in cp-Ti and
cp-Ti02 nano tubes. Without being bound to a particular
theory, this may be due to slightly lower biocompatibility of
the alloying elements (Aluminium and Vanadium) and their
oxides. Also, longer anodization duration resulted in longer
and more flexible nanotubes. Without being bound to a par
ticular theory, the surface of bare control samples showed the
lowest cell density, because the surface of bare control
samples has a very high mechanical stiffness (essentially the
elastic modulus of Ti). As the length of the nanotubes
increased beyond the length defined by an etching time of 4
hours, the cell density decreased (FIG. 18). This result indi
cates that there is an optimal nanotube length associated with
optimal bending stiffness.
FIB Milling Studies at Cell-Nanotube Interfaces
Focused ion beam (FIB) milling studies at cell-nanotube
interfaces provided evidence of the cell filopodia growth
inside the nanotubes, demonstrating a strong interlock
between the cell and substrate.
Initially, fibroblast adhesion to T i02 nanotubes was exam
ined by the FIB method and then this assay was extended to
osteoblast cells. The main reason to select fibroblasts for the
initial FIB work was that these cells make strong bonds with
most substrate materials. In addition, fibroblast cells are the
first to bond with the surface of the implant in in-vivo appli
cation of biomedical implants.
FIB milled fibroblast cells were obtained from a primary
ion beam (FIGS. 19A and 19B). The results show that fibro
blast filopodia strongly interacted with the cell’s nano-environment. Internal structures, membranes and morphological
stability and integrity are shown by the FIB method. The
interface between the cell and the substrate was observed in
the magnified cross sectional view of the cell-nanotube inter
face (FIGS. 20A-20D). After milling the cell by FIB, the
filopodia appeared to grow into the nano tubes. The results
also revealed that fibroblast sustained very high vacuum with
out visible damage and they physically survived ion beam
milling and imaging. Moreover, ion milling revealed many
internal features of cells at the submicron scale as well as the
high interaction and growth of the cells among the nanotubes.
The same FIB and SEM method was adapted to evaluate
osteoblast cell attachment and surface interaction. The inter
action of MC3T3 osteoblast cells with T i02 nanotubes was
analyzed by SEM (FIGS. 21B and 21C). The extension of
osteoblast cells for adhesion on the nanotubes, as well as cell
clusters (FIG. 21A) on the nanotube substrates, indicated the
ability of the nanotube structure to promote cell adhesion and
growth. As observed in the SEM images, the surface tended to
induce cell number, attachment, and spreading. The osteo
blast cells had a fully spread morphology (FIG. 21A) as well
as expansion of cell filopodia (FIGS. 21B and 21C). Attach
ment of cell filopodia to the nanotubes and filopodia expan
sion between the nanotubes was also observed. Thus, the
nano tubes acted as anchors for cell filopodia to grab (FIGS.
21F and 21G), increase spreading (FIG. 21D), and improve
attachment (FIG. 21G).
The evaluations of cell anchorage and interlock were per
formed by FIB milling and SEM. The architecture of the
cell/substrate interface was visualized by SEM (ion beam
imaging resolution is lower) to provide better insight into the
morphological and functional features of interfacial osteo
blast cell attachment. SEM images of the FIB milled cells
revealed that the nanotubes were completely clogged by the

cells (FIGS. 22A-22D). Even after removal of the cell top
section by FIB (FIGS. 22C and 22D) the nanotubes remain
clogged (FIGS. 22E and 13F) approximately 5 nm in depth
(FIG. 14). Clogging is due to high attachment of the cells
(qualitatively indicated from SEM images in FIGS. 21A-21G
and 22A-22E), indicating the well spread cell morphology
and the cell growth inside the hollow section of the nanotubes
(FIG. 23). The osteoblasts were in direct cell/substate con
tact with the nanotubes and were firmly attached to the sub
strate surface (FIGS. 22A-22E). EDS chemical analysis
showed that the bond between the nanotubes and the adjacent
osteoblast cell layer is composed of calcium and phosphorous
elements which therefore seemed to mimic the bond in the
bone tissue itself. On the substrate surface, cell filopodia and
the extracellular matrix remained attached following separa
tion from the milled top section of the cell (FIGS. 22A-22E
and 23). These observations revealed a close interfacial con
tact or direct contact between the osteoblasts and the nano
tubes followed by calcium and phosphorous deposition on the
nanotubes (FIG. 16). Calcium and phosphorous are the pri
mary components of bone matrix. The deposition of calcium
and phosphorous onto nanotubes was confirmed, indicating
that nanotubes maintained osteoblast functionality (FIG. 23).
The SEM images (FIG. 21G) and EDS analysis (FIG. 23)
showed that extracellular matrix (ECM) was secreted over the
surface of the sample and deposition of calcium and phos
phorous on the nanotubes, respectively. The cellular activity
of osteoblasts on the surface initiates with deposition of cal
cium and phosphorous as primary components of bone
matrix. This production of ECM on the nanotubes was
observed to be the result of osteoblast migration and health
cellular activity. Without being bound to a particular theory,
the nano tubes act as anchors for the cell filopodia to grab onto
and facilitate cell migration along the surface. The anchorage
benefit of nanotubes together with their strong hydrophilic
properties contributed to increased osteoblast density, spread
ing and attachment and achieved high-cohesion osseointegration.
The osteoblast cell culture experiments on the substrates
without nanotubes and substrates with nanotubes indicated
the presence of nanotube morphology increased cell density.
The nanotubes act as anchors for the cell filopodia to grab
onto and have facilitated migration along the surface. The
deposition of calcium and phosphorous which are the primary
components of bone matrix onto nanotubes indicates that
nanotubes have maintained osteoblast functionality. In view
of nanotube structure, the crystalline anatase nanotubes were
more effective in enhancing the cell growth in comparison to
the amorphous nanotubes probably due to increased hydrophilicity. From a geometrical perspective, the nanotubes with
the same crystalline structure and chemical composition, but
lower anodization duration and consequently smaller length
and diameter, showed higher cell density. The total cell den
sity in the bare control cp-Ti (Grade 2) and cp-Ti02 nanotubes
is slightly higher for all incubation periods, in comparison to
the total cell density in bare control Ti alloy (Grade 5) and
alloyed T i0 2 nanotubes. This behavior may be explained by
slightly lower biocompatibility of the alloying elements (A1
and V) and their oxides. EDS chemical analysis suggested
that the bond between the nanotube substrate and the adjacent
osteoblast cell layer is composed of calcium and phosphorous
elements which therefore seemed to mimic the bond in the
bone tissue itself. Based on FIB results, on the nanotube
covered surfaces, cells were observed to extend protrusions in
both the lateral and vertical directions, growing not only on
top of the nanotubes but also between and potentially down
into the open nanotube pores. This anchorage benefit of nano-
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tubes together with their strong hydrophilic properties
appears to have increased osteoblast density, spreading and
attachment for a promising high-cohesion osseointegration.
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Insertion torque measurements were graphed and a bare
screw was used as a control for comparison (FIG. 25). Inser
tion torque was compared between the bare control screw and
a nano tube-covered screw with a 3.2 mm diameter pilot hole
Example 5
5 with full radial thread engagement (FIG. 26). The nanotubecovered screws exhibited a lower insertion torque require
Nanotube Fabrication on Orthopedic Bone Screws
ment, perhaps because of the lower mechanical stiffness of
the surface. Without being bound to a particular theory, it has
To demonstrate the applicability of these processes in the
been hypothesized that this lower mechanical stiffness is
orthopedic industry and to show the structural robustness, 10
partially responsible for increased cell growth and adhesion.
nanotubes were fabricated on Ti6A14V ELI orthopedic bone
Nanotube Survivability
screws. These specimens were outdated surplus cancellous
Bone screws were inserted into and removed from bone
screws 6.5 mm OD and 3.2 mm ID (Linvatec of Laigo, Fla.).
stimulant
with a 5.0 mm diameter pilot hole and then inserted
Nanotubes were fabricated on the cancellous bone screws
using the standard setup with the screw connected to the 15 into and removed from bone stimulant with a 3.2 mm diam
eter hole. After undergoing these procedures, the bone screws
positive terminal and a graphite rod connected to electrical
were inspected in the SEM. Deposition of polyurethane on
ground. An approximate 12 mm portion of the end of the bone
top of the bone screw was observed as a result of tapping the
screw was immersed into the electrolyte and the circuit was
threaded hole in the bone stimulant. The polyurethane layer
energized at +60 VDC. After 15 minutes, the screw was
further immersed into the electrolyte an additional approxi- 20 had openings through which intact nanotubes were observed
(FIG. 27). To remove this contamination layer, the nanotube
mately 12 mm for an additional 15 minutes of etching time. In
covered screws were heated at 350° C. for 30 minutes to
this manner, the end portion of the screw had “30 minute
nano tubes” and the middle portion of the screw had “ 15
vaporize the polyurethane. The screw was then sonicated in
minute nano tubes.” The separation distance between the
water to remove any remaining debris. After this aggressive
screw and graphite rod was approximately 100 mm. Nano- 25 treatment, the screw was re-examined in the SEM confirming
tubes were observed to be fabricated over all regions of the
that the nanotubes had remained intact (FIG. 28).
bone screws (FIGS. 24A and 24B).
Thus, using graphite electrodes, nanotubular structures
Torque Insertion and Removal in Bone Simulant
were fabricated into Ti6A14V ELI surgical orthopedic can
To demonstrate the robustness of the nanotubes and to
cellous and cortical bone screws. The nanotubes on the bone
compare with predicted results from structural computer 30 screws survived multiple insertion and removal cycles in an
models, the nanotube covered bone screws were subjected to
accepted bone stimulant material.
super-physiological forces that may be encountered during
surgical implantation. Bone screws were selected because
Example 6
they experience shear and surface-normal forces during inser
tion into bone that are greater than during normal patient use. 35
Deposition o f Silver on T i0 2 Nanotube Surfaces
Additionally, screw loosening is an implant failure mecha
nism whereby increased bone adhesion can provide a solu
Nanotubes were fabricated onto and/or into the surface of
tion.
Ti6A14V titanium alloy by anodization using an AgF electro
lyte. T i0 2 nanotube surfaces made in this manner were stud
Bone stimulant material (Sawbones 1522-03, 20 pounds
per cubic foot polyurethane) had multiple pilot holes drilled 40 ied for the purpose of depositing silver on titanium surfaces.
The fabrication process used an etching system involving a
into it with recommended diameters obtained from the litera
Ti anode, a counter electrode, an electrolyte, and a DC power
ture for different conditions of bone. The pilot-hole diameters
source. The substrates for nanotube etching were flat, 2 cmx3
were 3.2 mm, 4.5 mm, 4.9 mm, and 5.0 mm. The bone screws
have a thread root diameter of 3.2 mm and an outside thread
cm area and 0.25 mm thickness, and polished with 0.06 mm
diameter of 6.5 mm. Therefore when screwed into the 3.2 mm 45 colloidal S i0 2. Prior to nanotube etching, the substrates were
diameter pilot holes, the screw threads have full radial
sequentially sonicated in acetone, isopropyl alcohol, and
engagement with the bone stimulant. When the screws are
methanol, then rinsed with deionized water and dried in an N2
inserted into larger diameter pilot holes, there is less radial
stream. The experimental setup consisted o f a two-electrode
thread engagement.
arrangement. Graphite was used as the counter electrode for
The screws were progressively inserted into the bone 50 the anodizations. The spacing between the substrates and the
counter electrode was approximately 25 mm. Etching condi
stimulant while measuring the required insertion torque.
tions were 60 VDC and a time of 30 minutes. The anodization
These measurements were accomplished by placing a force
was carried out at room temperature. The electrolyte was a
scale at the end of a hex wrench of the appropriate size for the
solution of AgF in 49 ml ethylene glycol and 1 ml deionized
bone screws. The maximum force required to turn the screws
at various depths of engagement were recorded. Each force 55 water (49 mL ethylene glycol, 1 mL water, and 0.9 grams of
silver fluoride). The innocuous etching electrolyte (AgF and
was multiplied by the perpendicular distance from the axis of
ethylene glycol rather than F1F) makes the process consider
the screw to the line of action of the force scale to obtain the
insertion torque.
ably safer, cheaper, and easier to maintain by eliminating the
need for costly specialized environmental containment and
Torque measurements were made over 3 insertion depth
regions of the screws. These regions were the ‘ 1st third” with 60 disposal safeguards. Additionally, it ensures that any residual
chemical etchant that might cling to the product surface
2-3 complete threads engaged into the bone stimulant mea
would be essentially benign. A constant 60 V DC was used for
sured from the screw tip, and subsequently the “2”d third’ with
all experiments. After anodization, the samples were rinsed
4-6 total threads engaged, and the V d third” with 7-9 total
with deionized water and dried in a N2 stream.
threads engaged. The screws used (45 mm total length) had a
Nanotubes were fabricated on titanium alloy Ti6A14V with
total of approximately 11 complete threads. Each torque data 65
point was calculated from 12 measurements for each “inser
the AgF-containing electrolyte (FIGS. 30A and 30B). The
tion third”.
nanotubes were approximately 2 microns in length.
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The T i02 nanotube fabrication process was modified so
that after anodization (etching conditions: 60 VDC; 30 min
utes), electrode polarity was immediately reversed. Again,
nanotubes on titanium alloy Ti6A14V were fabricated with
AgF-containing electrolyte (FIG. 31). When the T i0 2 nano
tube fabrication process included reversing the electrode
polarity for 15 minutes after anodization, silver was deposited
on the titanium substrate surface. X-ray elemental analysis
indicated that silver was deposited over the titanium substrate
surface, and that silver was the second most abundant element
after titanium. The titanium alloy is 6% by weight aluminum
and 4% by weight vanadium, and the silver content appeared
to be greater than either of these two alloy constituents. Thus,
T i02 nanotube surfaces comprising silver were generated.

surface onto/into which silver will be incorporated; and (2)
etch voltage, a higher etching voltage results in longer nano
tubes and more open volume among the nanotubes (as previ
ously shown) providing more surface onto or into which
silver will be incorporated.
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Example 7
Varying the Relative Presence of Silver in Nanotubes
The presence of silver in or on the nanotube surface can
confer anti-bacterial properties of the surface. However, the
amount of silver in or on the surface will impact those anti
bacterial properties. For example, too low of a silver content
has no adverse effect on bacteria whereas an overabundance
of silver, while it can act as an anti-bacterial agent, can dam
age normal tissue cells. The type of bacteria that are targeted
and the bacteria’s resiliency will dictate an acceptable range
of silver presence. It is therefore important to be able to adjust
the silver presence during the single process step of creating
silver-bearing titanium nanotubes.
Experiments were conducted to demonstrate this capabil
ity according to embodiments of the invention. As discussed
above, a nanotube-etching electrolyte is prepared by dissolv
ing a given amount of silver fluoride in 2 mL of deionized
water and 98 mL of ethylene glycol to produce a total of 100
mL of etching electrolyte. In this Example, the mass of silver
fluoride added to electrolyte was varied over a wide range,
namely 0.1 grams, 1.1 grams, and 2.25 grams per 100 mL of
electrolyte. Nanotubes were formed using 60 volts DC for a
total duration of 20 minutes. The relative presence of silver,
on both an atomic percent presence and a weight percent
presence was measured by energy-dispersive X-ray spectros
copy. The results are shown in FIG. 32.
As shown in FIG. 32, as the mass of silver fluoride present
in the same volume of electrolyte increases, the presence of
silver in the nanotube-covered sample surface rapidly
increases, such as a seven-fold increase in the percent pres
ence of silver atoms (diamonds, lower trace) and a five-fold
increase in the weight of silver present (squares, upper trace).
The results disclosed herein demonstrate the capability to
control the presence of silver which ends up in nanotubes
following etching, which can in turn be used to affect a
particular or several bacteria when lethal silver levels are
known for those bacteria. In various embodiments, the
amount of silver that is present during etching, which influ
ences the amount of silver that is associated with the modified
surface, may be varied in a range from 0.001 to 4 grams per
100 mL of electrolyte solution, including amounts of 0.01
grams, 0.5 grams, 1.0 grams, 1.5 grams, 2.0 grams, 3.0 grams,
and 3.5 grams per 100 mL.
In other embodiments, the relative amount of silver in the
final nanotube surface can be varied by varying the etching
parameters that control the size of the nano tubes. Larger and
longer nanotubes with more surface area will contain more
silver. These etching variables include: (1) etch time, a longer
etch time results in longer nanotubes and more open volume
among the nanotubes (as previously shown) providing more
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From the foregoing description, it will be apparent that
variations and modifications may be made to the invention
described herein to adopt it to various usages and conditions.
Such embodiments are also within the scope of the following
claims.
The recitation of a listing of elements in any definition of a
variable herein includes definitions of that variable as any
single element or combination (or subcombination) of listed
elements. The recitation of an embodiment herein includes
that embodiment as any single embodiment or in combination
with any other embodiments or portions thereof.
All patents and publications mentioned in this specification
are herein incorporated by reference to the same extent as if
each independent patent and publication was specifically and
individually indicated to be incorporated by reference.
What is claimed is:
1. A method for modifying a surface by generating nano
tubes at one or more selected sites on the surface, the surface
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode
relative to the surface in an electrolyte solution compris
ing a fluoride salt of a second metal; and
applying a voltage between the at least one anode and the at
least one cathode sufficient to generate nanotubes at one
or more selected sites on the surface by removing a
portion of the first metal from the surface by etching, and
to inhibit nanotube formation at one or more of the other
selected sites, wherein the nanotubes comprise the first
metal and the second metal;
wherein the electrolyte solution comprises AgF or CaF2.
2. The method of claim 1, further comprising applying a
voltage of reverse polarity to the at least one cathode and the
at least one anode sufficient to deposit the second metal onto
the surface.
3. The method of claim 1, wherein the first metal comprises
titanium.
4. The method of claim 3, wherein the second metal com
prises silver.
5. The method of claim 4, further comprising varying a
level o f silver in the electrolyte solution to vary an amount of
silver associated with the surface.
6. The method of claim 5, wherein varying a level of silver
in the electrolyte solution comprises adjusting a level of silver
in a range from 0.1 to 2.25 grams per 100 mL of electrolyte
solution.
7. The method of claim 6, wherein the electrolyte solution
comprises ethylene glycol and water.
8. The method of claim 1, wherein the at least one cathode
and the at least one anode comprise graphite.
9. The method of claim 1, wherein the second metal
reduces the propensity of the surface to support bacterial cell
growth.
10. The method of claim 1, wherein the voltage is approxi
mately 60 VDC.
11. The method of claim 1, wherein the surface comprises
titanium.
12. The method of claim 1, further comprising coating the
surface with at least one of an anti-bacterial agent, a growth
factor, and an anti-inflammatory agent.
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13. The method of claim 1, further comprising loading the
nanotubes with an effective amount of a biologically active
agent.
14. The method of claim 1, wherein the surface is present
on a biomedical implant or medical device.
15. The method of claim 1, wherein the surface is present
on a biomedical implant which is selected from the group
consisting of a dental implant, a cardiovascular implant, a
neurological implant, a neurovascular implant, a gastrointes
tinal implant, a muscular implant, an orthopedic implant, a
cochlear implant, and an ocular implant.
16. The method of claim 1, wherein the surface is present
on an orthopedic implant which is selected from the group
consisting of joint implants, spinal implants, screws, pins,
rods, and plates.
17. A method for modifying a surface by generating nano
tubes at one or more selected sites on the surface, the surface
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode
relative to the surface in an electrolyte solution compris
ing a fluoride salt of a second metal; and
applying a voltage between the at least one anode and the at
least one cathode sufficient to generate nanotubes at one
or more selected sites on the surface by removing a
portion of the first metal from the surface by etching, and
to inhibit nanotube formation at one or more of the other
selected sites, wherein the nanotubes comprise the first
metal and the second metal; and
applying a voltage of reverse polarity to the at least one
cathode and the at least one anode sufficient to deposit
the second metal onto the surface.
18. A method for modifying a surface by generating nano
tubes at one or more selected sites on the surface, the surface
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode
relative to the surface in an electrolyte solution compris
ing a fluoride salt of a second metal; and

applying a voltage between the at least one anode and the at
least one cathode sufficient to generate nanotubes at one
or more selected sites on the surface by removing a
portion of the first metal from the surface by etching, and
to inhibit nanotube formation at one or more of the other
selected sites, wherein the nanotubes comprise the first
metal and the second metal;
wherein the first metal comprises titanium, and the second
metal comprises silver.
19. The method of claim 18, further comprising varying a
level o f silver in the electrolyte solution to vary an amount of
silver associated with the surface.
20. The method of claim 19, wherein varying a level of
silver in the electrolyte solution comprises adjusting a level of
silver in a range from 0.1 to 2.25 grams per 100 mL of
electrolyte solution.
21. The method of claim 20, wherein the electrolyte solu
tion comprises ethylene glycol and water.
22. A method for modifying a surface by generating nano
tubes at one or more selected sites on the surface, the surface
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode
relative to the surface in an electrolyte solution compris
ing a fluoride salt of a second metal; and
applying a voltage between the at least one anode and the at
least one cathode sufficient to generate nanotubes at one
or more selected sites on the surface by removing a
portion of the first metal from the surface by etching, and
to inhibit nanotube formation at one or more of the other
selected sites, wherein the nanotubes comprise the first
metal and the second metal;
wherein the at least one cathode and the at least one anode
comprise graphite.
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